AHFS Classification – Drug Assignments
The following describes drug assignments and changes to the AHFS Pharmacologic-Therapeutic Classification©. This is only a partial listing of the AHFS classification system. The full classification, along with a list of drugs covered in AHFS DI and their corresponding classes, is available in the print edition of AHFS and electronically as a dataset that can be licensed. Reproduction, storage on a retrieval system, or transmission of this material or any part thereof in any form or by any means without the express written permission of the American Society of Health-System Pharmacists is prohibited.
Please contact us at ahfs@ashp.org if you have any questions.
AHFS Drug Assignments
| Drug Name | Active Ingredients | Company | Indication | Approval Date | AHFS Class | NDA Type | Appl No |
|---|---|---|---|---|---|---|---|
| Avmapki Fakzynja Co-Pack | avutometinib capsules/defactinib tablets | Verastem Oncology | KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer | 05/08/2025 | 10:00 - Antineoplastic Agents | ||
| Zevaskyn | prademagene zamikeracel | Abeona Therapeutics Inc. | Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa | 04/29/2025 | 26:12 - Gene Therapy; 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | ||
| Imaavy | nipocalimab-aahu | Janssen Biotech, Inc. | Generalized Myasthenia Gravis (gMG) | 04/29/2025 | 90:08.04 - Neonatal Fc Receptor Blockers | BLA | 761430 |
| Penpulimab-kcqx | Akeso, Inc. | Advanced Nasopharyngeal Carcinoma | 04/23/2025 | 10:00 - Antineoplastic Agents | BLA/O | 761258 | |
| Vanrafia | atrasentan | Novartis Pharmaceuticals Corp | Proteinuria Reduction in Primary IgA Nephropathy | 04/02/2025 | 48:48.12 - Endothelin receptor antagonists | 1P | 219208 |
| Qfitlia | fitusiran | Genzyme corp | Hemophilia A or B With or Without Inhibitors | 03/28/2025 | 20:28.16 - Hemostatics | 1S/O | 219019 |
| Vykat XR | diazoxide choline | Soleno Therapeutics, Inc. | Hyperphagia in Prader-Willi Syndrome | 03/26/2025 | 28:20.92 - Anorexigenic Agents and Stimulants, Miscellaneous | 2P/O | 216665 |
| Blujepa | gepotidacin | GSK | Uncomplicated Urinary Tract Infections | 03/25/2025 | 8:12.28.36 - Triazaacenaphthylenes | 1P | 218230 |
| Encelto | revakinagene taroretcel-lwey | Neurotech Pharmaceuticals, Inc. | Macular Telangiectasia Type 2 (MacTel) | 03/06/2025 | 26:12 - Gene Therapy; 52:92 - EENT Drugs, Miscellaneous | ||
| Vimkunya | chikungunya vaccine, recombinant | Bavarian Nordic A/S | Prevention of Disease Caused by Chikungunya Virus | 02/14/2025 | 80:12 - Vaccines | ||
| Romvimza | vimseltinib | Ono Pharmaceutical Co., Ltd. | Symptomatic Tenosynovial Giant Cell Tumor | 02/14/2025 | 10:00 - Antineoplastic Agents | 1P | |
| Gomekli | mirdametinib | SpringWorks Therapeutics, Inc. | Adult and Pediatric Patients with NF1-PN | 02/11/2025 | 10:00 - Antineoplastic Agents | ||
| Emblaveo | aztreonam and avibactam | AbbVie | Complicated Intra-Abdominal Infections | 02/07/2025 | 8:12.07.16 - Monobactams | ||
| Symbravo | meloxicam and rizatriptan | Axsome Therapeutics, Inc. | Acute Treatment of Migraine with or without Aura in Adults | 01/30/2025 | 28:32.28 - Selective Serotonin Agonists; 28:08.04.04 - Reversible COX-1/COX-2 Inhibitors | ||
| Journavx | suzetrigine | Vertex Pharmaceuticals | Moderate-to-Severe Acute Pain | 01/30/2025 | 28:08.92 - Analgesics and Antipyretics, Miscellaneous | 1P | |
| Grafapex | treosulfan | Medexus | Allogeneic Hematopoietic Stem Cell Transplantation | 01/22/2025 | 10:00 - Antineoplastic Agents | ||
| Datroway | datopotamab deruxtecan-dlnk | Daiichi Sankyo | Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer | 01/17/2025 | 10:00 - Antineoplastic Agents | BLA | |
| Alhemo | concizumab-mtci | Novo Nordisk | Prevent or Reduce Bleeding Episodes in People with Hemophilia A or B with Inhibitors | 12/20/2024 | 20:28.16 - Hemostatics | BLA | |
| Alyftrek | Vanzacaftor/Tezacaftor/Deutivacaftor | Vertex Pharms INC | Cystic Fibrosis | 12/20/2024 | 48:14.04 - Cystic Fibrosis Transmembrane Conductance Regulator Correctors; 48:14.12 - Cystic Fibrosis Transmembrane Conductance Regulator Potentiators | 1P/O | |
| Tryngolza | olezarsen | Ionis Pharmaceuticals, Inc. | Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome | 12/19/2024 | 24:06.92 - Antilipemic Agents, Miscellaneous | 1P | |
| Ensacove | ensartinib | Xcovery Holdings, Inc. | ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/18/2024 | 10:00 - Antineoplastic Agents | 1S | |
| Ryoncil | remestemcel-L-rknd | Mesoblast, Inc. | steroid-refractory acute graft versus host disease in pediatric patients | 12/18/2024 | 26:04 - Cellular Therapy | ||
| Unloxcyt | cosibelimab-ipdl | Checkpoint Therapeutics, Inc. | Cutaneous Squamous Cell Carcinoma | 12/13/2024 | 10:00 - Antineoplastic Agents | BLA | |
| Crenessity | crinecerfont | Neurocrine Biosciences, Inc. | Classic Congenital Adrenal Hyperplasia | 12/13/2024 | 68:28 - Pituitary | 1P | |
| Bizengri | zenocutuzumab-zbco | Merus N.V. | NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer | 12/04/2024 | 10:00 - Antineoplastic Agents | BLA/O | |
| Iomervu | Iomeprol | Bracco Diagnostics INC | diagnostic imaging procedures with chemical properties similar to another iodinated contrast agent iopromide (nonionic, low osmolality) | 11/27/2024 | 36:68 - Roentgenography | ||
| Rapiblyk | landiolol | AOP Orphan Pharmaceuticals GmbH | Atrial Fibrillation and Atrial Flutter in the Critical Care Setting | 11/22/2024 | 24:20 - beta-Adrenergic Blocking Agents | 1S | |
| Attruby | acoramidis | BridgeBio Pharma, Inc. | Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Patients with ATTR-CM | 11/22/2024 | 24:04.92 - Cardiac Drugs, Miscellaneous | 1S/O | |
| Revuforj | revumenib | Syndax Pharmaceuticals | Relapsed or Refractory Acute Leukemia with a KMT2A Translocation | 11/15/2024 | 10:00 - Antineoplastic Agents | 1P | |
| Kebilidi | eladocagene exuparvovec-tneq | PTC Therapeutics, Inc. | AADC Deficiency | 11/13/2024 | 26:12 - Gene Therapy | ||
| Aucatzyl | obecabtagene autoleucel | Autolus Therapeutics plc | Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | 11/08/2024 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | ||
| Orlynvah | sulopenem etzadroxil and probenecid | Iterum Therapeutics plc | Uncomplicated Urinary Tract Infections | 10/25/2024 | 8:36 - Urinary Anti-infectives | 1/4 P | |
| Vyloy | zolbetuximab-clzb | Astellas Pharma Inc. | Advanced Gastric and GEJ Cancer | 10/18/2024 | 10:00 - Antineoplastic Agents | BLA/O | |
| Vyalev | foscarbidopa and foslevodopa | AbbVie | Advanced Parkinson's Disease | 10/16/2024 | 28:36.16 - Dopamine Precursors | 3/4 S/O | |
| Hympavzi | Marstacimab-hncq | Pfizer Inc. | Hemophilia A or B Without Inhibitors | 10/11/2024 | 20:28.16 - Hemostatics | BLA/O | |
| Itovebi | inavolisib | Genentech | Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation | 10/10/2024 | 10:00 - Antineoplastic Agents | S | |
| Flyrcado | flurpiridaz F 18 | GE HealthCare | evaluate for myocardial ischemia (cardiac function disorder when the heart muscle doesn’t receive enough blood flow to function properly) and infarction (heart attack) | 09/27/2024 | 36:68 - Roentgenography | 1S | |
| Cobenfy | xanomeline and trospium chloride | Bristol Myers Squibb | Schizophrenia | 09/26/2024 | 28:16.08.92 - Antipsychotics, Miscellaneous; 86:12.04 - Antimuscarinics | 1P | |
| Aqneursa | levacetylleucine | IntraBio Inc. | Niemann-Pick Disease Type C | 09/24/2024 | 92:92 - Other Miscellaneous Therapeutic Agents | ||
| Miplyffa | arimoclomol | Zevra Therapeutics, Inc. | Niemann-Pick Disease Type C | 09/20/2024 | 44:08 - Enzyme Cofactors/Chaperones | 1P/O | |
| EBGLYSS | lebrikizumab-lbkz | Eli Lilly and Company | Moderate-to-Severe Atopic Dermatitis | 09/13/2024 | 84:06.28 - Immunomodulatory Agents | BLA | |
| Rybrevant Plus Lazcluze | amivantamab-vmjw plus lazertinib | Janssen Biotech, Inc. | EGFR-Mutated Advanced Lung cancer | 08/20/2024 | 10:00 - Antineoplastic Agents | ||
| Niktimvo | axatilimab-csfr | Incyte | Chronic Graft-Versus-Host Disease (GVHD) | 08/14/2024 | 92:92 - Other Miscellaneous Therapeutic Agents | BLA | |
| Livdelzi | seladelpar | Gilead Sciences, Inc. | Primary Biliary Cholangitis | 08/14/2024 | 56:14 - Cholelitholytic Agents | 1P/O | |
| Nemluvio | nemolizumab | Galderma | 08/12/2024 | 84:06.28 - Immunomodulatory Agents | BLA | ||
| Yorvipath | palopegteriparatide | Ascendis Pharma A/S | Hypoparathyroidism | 08/09/2024 | 68:24.08 - Parathyroid Agents | 1P/O | |
| Lymphir | denileukin diftitox-cxdl | Citius Pharmaceuticals, Inc. | Relapsed or Refractory Cutaneous T-Cell Lymphoma | 08/07/2024 | 10:00 - Antineoplastic Agents | BLA/O | |
| Voranigo | vorasidenib | Servier Pharmaceuticals. | Grade 2 IDH-Mutant Glioma | 08/06/2024 | 10:00 - Antineoplastic Agents | ||
| Tecelra | afamitresgene autoleucel | Adaptimmune, LLC. | Metastatic Synovial Sarcoma | 08/02/2024 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | ||
| Zunveyl | benzgalantamine | Alpha Cognition | Alzheimer's Disease | 07/26/2024 | 12:04 - Parasympathomimetic (Cholinergic) Agents | ||
| Leqselvi | deuruxolitinib | Sun Pharmaceutical Industries Limited. | Severe Alopecia Areata | 07/25/2024 | 84:06.16 - Janus Kinase Inhibitors | 1S | |
| Kisunla | donanemab-azbt | Eli Lilly and Company | Early Symptomatic Alzheimer's Disease | 07/02/2024 | 90:10.04 - Monoclonal Antibodies | BLA | |
| Ohtuvayre | Ensifentrine | Verona Pharma plc | Chronic Obstructive Pulmonary Disease (COPD) | 06/26/2024 | 48:34 - Dual Phosphodiesterase Inhibitors | ||
| Piasky | crovalimab-akkz | Genetech Inc | paroxysmal nocturnal hemoglobinuria | 06/20/2024 | 90:20 - Complement Inhibitor Agents | BLA/O | |
| Sofdra | sofpironium | Botanix Pharmaceuticals Ltd. | Primary Axillary Hyperhidrosis | 06/18/2024 | 84:12 - Astringents | ||
| Capvaxive | pneumococcal 21-valent conjugate vaccine | Merck & Co., Inc. | Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults | 06/17/2024 | 80:12 - Vaccines | ||
| Iqirvo | elafibranor | Ipsen | Primary Biliary Cholangitis | 06/10/2024 | 56:14 - Cholelitholytic Agents | ||
| Rytelo | imetelstat | Geron Corporation | Lower-Risk MDS with Transfusion-Dependent Anemia | 06/06/2024 | 10:00 - Antineoplastic Agents | 1S/O | |
| mRESVIA | respiratory syncytial virus vaccine | Moderna, Inc. | Prevention of Lower Respiratory Tract Disease Caused by RSV | 05/31/2024 | 80:12 - Vaccines | ||
| Imdelltra | tarlatamab-dlle | Amgen | Extensive-Stage Small Cell Lung Cancer | 05/16/2024 | 10:00 - Antineoplastic Agents | BLA | |
| Beqvez | fidanacogene elaparvovec-dzkt | Pfizer Inc. | hemophilia B | 04/26/2024 | 26:12 - Gene Therapy | ||
| Xolremdi | mavorixafor | X4 Pharmaceutical Inc. | WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) | 04/26/2024 | 20:16 - Hematopoietic Agents | ||
| Pivya | pivmecillinam | UTILITY therapeutics Ltd. | uncomplicated urinary tract infections (UTIs) | 04/24/2024 | 8:12.16.08 - Aminopenicillins | ||
| Ojemda | tovorafenib | Day One Biopharmaceuticals, Inc. | Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma | 04/23/2024 | 10:00 - Antineoplastic Agents | 1P/O | |
| Anktiva | nogapendekin alfa inbakicept-pmln | Altor BioScience, LLC | BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors | 04/22/2024 | 10:00 - Antineoplastic Agents | BLA | |
| Zevtera | ceftobiprole medocaril | Basilea Pharmaceutica International Ltd | Staphylococcus aureus bloodstream infections (bacteremia) (SAB), acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) | 04/03/2024 | 8:12.06.20 - Fifth Generation Cephalosporins | ||
| Voydeya | danicopan | AstraZeneca | Add-On Therapy for the Treatment of Extravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria | 04/01/2024 | 92:32.08 - Complement Inhibitors | ||
| Vafseo | vadadustat | Akebia Therapeutics, Inc. | Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis | 03/27/2024 | 20:16 - Hematopoietic Agents | 1S | |
| Winrevair | sotatercept-csrk | Merck & Co., Inc. | Pulmonary Arterial Hypertension | 03/26/2024 | 48:92 - Respiratory Tract Agents, Miscellaneous | BLA | |
| Opsynvi | macitentan and tadalafil | Actelion Pharmaceuticals US, Inc. | Pulmonary Arterial Hypertension | 03/22/2024 | 48:48.12 - Endothelin receptor antagonists; 48:48.24 - Phosphodiesterase Type 5 Inhibitors | 4S/O | |
| Pemgarda | pemivibart | Invivyd, Inc. | pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents | 03/22/2024 | 8:18.24 - Monoclonal Antibodies | ||
| Duvyzat | givinostat | Italfarmaco S.p.A. | Duchenne Muscular Dystrophy (DMD) in patients six years of age and older | 03/21/2024 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | |
| Tryvio | aprocitentan | Idorsia Pharmaceuticals U.S. Inc. | Resistant Hypertension | 03/19/2024 | 24:52 - Endothelin Receptor Antagonists | 1S | |
| Lenmeldy | atidarsagene autotemcel | Orchard Therapeutics | Children with Metachromatic Leukodystrophy | 03/18/2024 | 26:12 - Gene Therapy | ||
| Rezdiffra | resmetirom | Madrigal Pharmaceuticals | metabolic dysfunction–associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (consistent with stage F2 and F3 disease) | 03/14/2024 | 56:92 - GI Drugs, Miscellaneous | 1P | |
| Tevimbra | Tislelizumab-jsgr | BeiGene | unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy | 03/13/2024 | 10:00 - Antineoplastic Agents | BLA/O | |
| Letybo | letibotulinumtoxinA-wlbg | Hugel America, Inc. | Glabellar Lines | 02/29/2024 | 12:20.20.24 - Botulinum toxins | BLA | |
| Exblifep | cefepime/enmetazobactam | Allecra Therapeutics | Complicated Urinary Tract Infections | 02/22/2024 | 8:12.06.16 - Fourth Generation Cephalosporins | 1/4P | |
| Amtagvi | lifileucel | Iovance Biotherapeutics Inc. | Unresectable or Metastatic Melanoma | 02/16/2024 | 26:04 - Cellular Therapy | ||
| Aurlumyn | iloprost | Eicos Sciences Inc. | severe frostbite | 02/13/2024 | 24:08.92 - Vasodilating Agents, Miscellaneous | 3P/0 | |
| Zelsuvmi | berdazimer topical gel | Ligand Pharmaceuticals Incorporated | Molluscum Contagiosum | 01/05/2024 | 84:04.06 - Antivirals | ||
| Wainua | eplontersen | Ionis Pharmaceuticals, Inc. | Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis | 12/21/2023 | 92:18 - Antisense Oligonucleotides | 1S/O | |
| Filsuvez | birch triterpenes | Chiesi Global Rare Diseases | Epidermolysis Bullosa | 12/19/2023 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | ||
| Iwilfin | eflornithine | USWM, LLC | Maintenance Therapy for High-Risk Neuroblastoma | 12/13/2023 | 10:00 - Antineoplastic Agents | P/O | |
| Lyfgenia | lovotibeglogene autotemcel | bluebird bio, Inc. | Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events | 12/08/2023 | 26:12 - Gene Therapy | ||
| Casgevy | exagamglogene autotemcel | CRISPR Therapeutics AG | Sickle Cell Disease | 12/08/2023 | 26:12 - Gene Therapy | ||
| Fabhalta | iptacopan | Novartis | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 12/05/2023 | 92:32.08 - Complement Inhibitors | 1P/O | |
| Ogsiveo® | Nirogacestat | SpringWorks Therapeutics Inc. | desmoid tumors, a rare subtype of soft tissue sarcomas | 11/27/2023 | 10:00 - Antineoplastic Agents | 1P/O | |
| Ryzneuta® | Efbemalenograstim alfa | Evive Biotec | Chemotherapy-Induced Neutropenia | 11/16/2023 | 20:16 - Hematopoietic Agents | BLA | |
| Truqap® | Capivasertib | AstraZeneca | hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer | 11/16/2023 | 10:00 - Antineoplastic Agents | 1P | |
| Augtyro® | Repotrectinib | Bristol Myers Squibb | Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) | 11/15/2023 | 10:00 - Antineoplastic Agents | 1P/O | |
| DefenCath | taurolidine and heparin | CorMedix Inc. | Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients | 11/15/2023 | 8:12.28 - Antibacterials, Miscellaneous; 20:12.04.16 - Heparins | 1/4P | |
| Ixchiq® | Chikungunya Vaccine, Live | Valneva Austria GmbH | chikungunya virus | 11/09/2023 | 80:12 - Vaccines | ||
| Adzynma® | ADAMTS13, recombinant-krhn | Takeda | congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder | 11/09/2023 | 44:00 - Enzymes | ||
| Zepbound® | Tirzepatide | Eli Lilly and Company | Chronic Weight Management | 11/08/2023 | 68:20.06 - Incretin Mimetics; 28:20.08.92 - Anorexigenic Agents, Miscellaneous | P | |
| Fruzaqla® | Fruquintinib | Takeda | metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy | 11/08/2023 | 10:00 - Antineoplastic Agents | 1P | |
| Loqtorzi® | toripalimab-tpzi | Coherus BioSciences, Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | 10/27/2023 | 10:00 - Antineoplastic Agents | BLA/O | |
| Agamree® | vamorolone | Catalyst Pharmaceuticals, Inc. | Duchenne Muscular Dystrophy | 10/26/2023 | 68:04 - Adrenals | 1S/O | |
| Omvoh® | mirikizumab-mrkz | Eli Lilly and Company | Moderately to Severely Active Ulcerative Colitis | 10/26/2023 | 56:44 - Immunomodulatory Agents | ||
| Penbraya® | meningococcal groups A, B, C, W and Y vaccine | Pfizer Inc. | Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents | 10/20/2023 | 80:12 - Vaccines | ||
| Xphozah® | tenapanor | Ardelyx | high phosphate levels in patients with chronic kidney disease (CKD) | 10/18/2023 | 40:18.19 - Phosphate-reducing Agents | ||
| Zilbrysq® | zilucoplan | UCB Inc | Generalized Myasthenia Gravis | 10/17/2023 | 92:32.08 - Complement Inhibitors | 1S/O | |
| Bimzelx® | bimekizumab-bkzx | UCB Inc | Moderate-To-Severe Plaque Psoriasis | 10/17/2023 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | ||
| Velsipity® | etrasimod | Pfizer Inc. | moderately to severely active ulcerative colitis | 10/12/2023 | 56:44 - Immunomodulatory Agents | 1S | |
| Rivfloza® | nedosiran | Novo Nordisk Inc. | Primary Hyperoxaluria Type 1 (PH1) | 09/29/2023 | 92:92 - Other Miscellaneous Therapeutic Agents | 1S/O | |
| Opfolda™ | miglustat | Amicus Therapeutics | late-onset Pompe disease (LOPD) | 09/28/2023 | 92:92 - Other Miscellaneous Therapeutic Agents | 5S/O | |
| Pombiliti™ | cipaglucosidase alfa-atga | Amicus Therapeutics | late-onset Pompe disease (LOPD) | 09/28/2023 | 44:00 - Enzymes | ||
| Ryzumvi® | phentolamine | Ocuphire Pharma, Inc. | Pharmacologically-Induced Mydriasis | 09/25/2023 | 52:92 - EENT Drugs, Miscellaneous | 3S | |
| Exxua® | gepirone | Fabre-Kramer Pharmaceuticals Inc. | Major Depressive Disorder in Adults | 09/22/2023 | 28:16.04.24 - Serotonin Modulators | 1S | |
| Ojjaara® | momelotinib | GSK plc | Myelofibrosis Patients with Anemia | 09/15/2023 | 10:00 - Antineoplastic Agents | 1S | |
| Aphexda® | motixafortide | BioLineRx Ltd. | Mobilize Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma | 09/08/2023 | 20:16 - Hematopoietic Agents | 1S/O | |
| Veopoz® | pozelimab-bbfg | Regeneron Pharmaceuticals, Inc. | CHAPLE Disease | 08/18/2023 | 92:32.08 - Complement Inhibitors | BLA/O | |
| Sohonos™ | palovarotene | Ipsen | fibrodysplasia ossificans progressiva | 08/16/2023 | 92:92 - Other Miscellaneous Therapeutic Agents | ||
| Elrexfio® | elranatamab-bcmm | Pfizer Inc. | Relapsed or Refractory Multiple Myeloma | 08/14/2023 | 10:00 - Antineoplastic Agents | ||
| Akeega® | niraparib and abiraterone acetate | Janssen Biotech | BRCA-Positive Metastatic Castration-Resistant Prostate Cancer | 08/11/2023 | 10:00 - Antineoplastic Agents | 4P | |
| Talvey® | talquetamab-tgvs | Janssen Biotech | Heavily Pretreated Multiple Myeloma | 08/09/2023 | 10:00 - Antineoplastic Agents | BLA/O | |
| Izervay® | avacincaptad pegol | Astellas Pharma Inc. | Geographic Atrophy | 08/05/2023 | 52:92 - EENT Drugs, Miscellaneous | ||
| Zurzuvae® | zuranolone | Sage Therapeutics, Inc. | Postpartum Depression | 08/04/2023 | 28:16.04.92 - Antidepressants, Miscellaneous | ||
| Xdemvy® | lotilaner | Tarsus Pharmaceuticals, Inc | Demodex Blepharitis | 07/24/2023 | 52:04.92 - Anti-infectives, Miscellaneous | 1S | |
| Ycanth® | cantharidin | Verrica Pharmaceuticals Inc | Molluscum Contagiosum | 07/21/2023 | 84:04.06 - Antivirals | 5S | |
| Vanflyta® | quizartinib | Daiichi Sankyo | Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia | 07/20/2023 | 10:00 - Antineoplastic Agents | 1P/O | |
| Cyfendus® | Anthrax Vaccine Adsorbed, Adjuvanted | Emergent BioSolutions Inc | post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs | 07/20/2023 | 80:12 - Vaccines | ||
| Beyfortus® | nirsevimab | AstraZeneca / Sanofi | Prevention of RSV Lower Respiratory Tract Disease in Infants | 07/17/2023 | 8:18.24 - Monoclonal Antibodies | ||
| Roctavian® | valoctocogene roxaparvovec-rvox | BioMarin Pharmaceutical Inc. | Hemophilia A | 06/29/2023 | 26:12 - Gene Therapy | ||
| Ngenla® | somatrogon-ghla | Pfizer Inc. | Pediatric Growth Hormone Deficiency | 06/28/2023 | 68:28 - Pituitary | ||
| Lantidra® | donislecel-jujn | CellTrans Inc. | Type 1 Diabetes | 06/28/2023 | 26:04 - Cellular Therapy | ||
| Rystiggo® | rozanolixizumab-noli | UCB Inc | Generalized Myasthenia Gravis | 06/26/2023 | 92:20 - Immunomodulatory Agents | BLA/O | |
| Litfulo® | ritlecitinib | Pfizer Inc. | Severe Alopecia Areata | 06/23/2023 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 1S | |
| Elevidys® | delandistrogene moxeparvovec-rokl | Sarepta Therapeutics, Inc. | Duchenne Muscular Dystrophy | 06/22/2023 | 26:12 - Gene Therapy | ||
| Columvi® | glofitamab-gxbm | Genentech Inc | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 06/15/2023 | 10:00 - Antineoplastic Agents | BLA | |
| Abrysvo® | respiratory syncytial virus vaccine | Pfizer Inc. | Prevention of Respiratory Syncytial Virus (RSV) | 05/31/2023 | 80:12 - Vaccines | ||
| Inpefa® | sotagliflozin | Lexicon Pharmaceuticals INC | reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors | 05/26/2023 | 24:40 - Sodium-glucose (SGLT) Cotransporter Inhibitors | 1S | |
| Posluma® | flotufolastat F-18 | Blue Earth Diagnostics LTD. | positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer | 05/25/2023 | 36:68 - Roentgenography | 1S | |
| Xacduro® | sulbactam and durlobactam | Innoviva, Inc. | Serious Infections Caused by Acinetobacter | 05/23/2023 | 8:12.28.92 - Other Miscellaneous Antibacterials | ||
| Epkinly® | epcoritamab-bysp | AbbVie and Genmab | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | 05/19/2023 | 10:00 - Antineoplastic Agents | BLA/O | |
| Vyjuvek™ | beremagene geperpavec-svdt | Krystal Biotech, Inc. | Dystrophic Epidermolysis Bullosa | 05/19/2023 | 26:12 - Gene Therapy | ||
| Miebo® | perfluorohexyloctane | Bausch and Lomb INC | signs and symptoms of dry eye disease. | 05/18/2023 | 52:92 - EENT Drugs, Miscellaneous | 1S | |
| Veozah® | fezolinetant | Astellas Pharma Inc. | Vasomotor Symptoms Due to Menopause | 05/12/2023 | 28:92 - Central Nervous System Agents, Miscellaneous | 1P | |
| Elfabrio® | pegunigalsidase alfa-iwxj | Chiesi Farmaceutici S.p.A. | Fabry disease | 05/09/2023 | 44:00 - Enzymes | BLA/O | |
| Arexvy® | respiratory syncytial virus vaccine, adjuvanted | GlaxoSmithKline Biologicals. | prevention of lower respiratory tract disease cause by RSV in individuals 60 years of age and older | 05/03/2023 | 80:12 - Vaccines | ||
| Vowst® | fecal microbiota spores, live-brpk | Seres Therapeutics, Inc. | prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI | 04/26/2023 | 92:92 - Other Miscellaneous Therapeutic Agents | ||
| Qalsody® | tofersen | Biogen Inc. | Amyotrophic Lateral Sclerosis Associated with a Mutation in the SOD1 Gene | 04/25/2023 | 28:92 - Central Nervous System Agents, Miscellaneous; 92:18 - Antisense Oligoonucleotides | 1P/O | |
| Omisirge® | omidubicel-onlv | Gamida-Cell Ltd. | blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy) | 04/17/2023 | 26:04 - Cellular Therapy | ||
| Gohibic® | vilobelimab | InflaRx | COVID-19 | 04/04/2023 | 8:18.24 - Monoclonal Antibodies | ||
| Joenja® | leniolisib | Pharming Technologies B.V. | activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS) | 03/24/2023 | 92:20 - Immunomodulatory Agents | 1P/O | |
| Zynyz® | retifanlimab-dlwr | Incyte Corp. | Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC) | 03/22/2023 | 10:00 - Antineoplastic Agents | BLA/O | |
| Rezzayo® | rezafungin | Cidara Therapeutics, Inc. | Candidemia and Invasive Candidiasis | 03/22/2023 | 8:14.16 - Echinocandins | ||
| Daybue® | trofinetide | Acadia Pharms Inc. | Rett syndrome | 03/10/2023 | 28:92 - Central Nervous System Agents, Miscellaneous | 1P/O | |
| Zavzpret® | zavegepant | Pfizer Inc. | acute treatment of migraine with or without aura in adults | 03/09/2023 | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists | 1S | |
| Skyclarys® | omaveloxolone | Reata Pharmaceuticals, Inc. | Friedreich’s ataxia in adults and adolescents aged 16 years and older. | 02/28/2023 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P | |
| Altuviiio™ | antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl | Bioverativ Therapeutics Inc., a Sanofi Company | For adults and children with Hemophilia A (congenital Factor VIII deficiency) for: (1) Routine prophylaxis to reduce the frequency of bleeding episodes; (2) On-demand treatment and control of bleeding episodes; and (3) Perioperative management of bleeding | 02/23/2023 | 20:28.16 - Hemostatics | ||
| Filspari® | sparsentan | Travere Therapeutics, Inc. | Reduction of Proteinuria in IgA Nephropathy | 02/17/2023 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P | |
| Syfovre® | pegcetacoplan | Apellis Pharmaceuticals, Inc. | geographic atrophy (GA) | 02/17/2023 | 52:92 - EENT Drugs, Miscellaneous | 3P | |
| Lamzede® | velmanase alfa-tycv | Chiesi Farmaceutici S.p.A. | non-central nervous system manifestations of alpha-mannosidosis | 02/16/2023 | 44:00 - Enzymes | BLA/O | |
| Jesduvroq® | daprodustat | GlaxoSmithKline LLC | Anemia Caused by Chronic Kidney Disease for Adults on Dialysis | 02/01/2023 | 20:16 - Hematopoietic Agents ; 20:04 - Antianemia Drugs | 1S | |
| JAYPIRCA® | pirtobrutinib | Loxo Oncology Inc | relapsed or refractory mantle cell lymphoma (MCL) | 01/27/2023 | 10:00 - Antineoplastic Agents | 1P/O | |
| Orserdu® | elacestrant | Stemline Therapeutics Inc | postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy | 01/27/2023 | 10:00 - Antineoplastic Agents | 1P | |
| Brenzvvy® | bexaglifozin | Theraxosbio LLC | type 2 diabetes mellitus | 01/20/2023 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors | 1S | |
| Airsupra® | albuterol/budesonide | Bond Avillion 2 Development LP | as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations | 01/10/2023 | 68:04 - Adrenals; 12:12.08.12 - Selective beta-2-Adrenergic Agonists; 48:12.04.12 - Selective beta-2-Adrenergic Agonists; 48:10.08.08 - Orally Inhaled Preparations | 4S | |
| Leqembi® | lecanemab-irmb | Eisai Inc | Alzheimer's disease | 01/06/2023 | 28:92 - Central Nervous System Agents, Miscellaneous | BLA | |
| NexoBrid® | anacaulase-bcdb | MediWound, Ltd | eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns | 12/28/2022 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | BLA/O | |
| Briumvi® | ublituximab-xiiy | TG Therapeutics, Inc | Relapsing Forms of Multiple Sclerosis | 12/28/2022 | 92:20 - Immunomodulatory Agents | BLA | |
| Lunsumio® | mosunetuzumab-axgb | Genentech Inc | Relapsed or Refractory Follicular Lymphoma | 12/22/2022 | 10:00 - Antineoplastic Agents | BLA/O | |
| Sunlenca® | lenacapavir | Gilead Sciences | HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations | 12/22/2022 | 8:18.08.24 - HIV Capsid Inhibitors | 1P | |
| Adstiladrin® | nadofaragene firadenovec-vncg | Ferring Pharmaceuticals | high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. | 12/16/2022 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | ||
| Krazati® | adagrasib | Mirati Therapeutics, Inc. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation | 12/12/2022 | 10:00 - Antineoplastic Agents | 1S | |
| Rezlidhia® | olutasidenib | Forma Therapeutics, Inc. | relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation | 12/01/2022 | 10:00 - Antineoplastic Agents | 1S/O | |
| Rebyota® | fecal microbiota, live-jslm | Ferring Pharmaceuticals | prevention of recurrence of Clostridioides difficile (C. diff) infection | 11/30/2022 | 92:92 - Other Miscellaneous Therapeutic Agents | ||
| Hemgenix® | etranacogene dezaparvovec-drlb | CSL Behring | Gene Therapy for Hemophilia B | 11/22/2022 | 26:12 - Gene Therapy; 20:28.16 - Hemostatics | ||
| Tzield® | teplizumab-mzwv | Provention Bio Inc | Delay onset of stage 3 type 1 diabetes | 11/17/2022 | 68:20.92 - Antidiabetic Agents, Miscellaneous | BLA | |
| Elahere® | mirvetuximab soravtansine-gynx | Immunogen INC | Platinum-Resistant Ovarian Cancer | 11/14/2022 | 10:00 - Antineoplastic Agents | BLA/O | |
| Tecvayli® | teclistamab-cqyv | Janssen | Relapsed or Refractory Multiple Myeloma | 10/25/2022 | 10:00 - Antineoplastic Agents | BLA/O | |
| Imjudo® | tremelimumab-actl | AstraZeneca | Unresectable Hepatocellular Carcinoma | 10/24/2022 | 10:00 - Antineoplastic Agents | BLA/O | |
| Lytgobi® | Futibatinib | Taiho Oncology, Inc. | Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | 09/30/2022 | 10:00 - Antineoplastic Agents | 1P/O | |
| Relyvrio® | Sodium phenylbutyrate/taurursodiol | Amylyx Pharmaceuticals, Inc. | Amyotrophic Lateral Sclerosis (ALS) | 09/29/2022 | 28:92 - Central Nervous System Agents, Miscellaneous | 1P/O | |
| Omlonti® | Omidenepag isopropyl | Santen Inc. | reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension | 09/22/2022 | 52:40.92 - Antiglaucoma Agents, Miscellaneous | 1S | |
| Elucirem® | gadopiclenol | Guerbet | contrast-enhanced magnetic resonance imaging (MRI) | 09/22/2022 | 36:68 - Roentgenography | 1/4P | |
| Pedmark® | Sodium Thiosulfate | Fennec Pharmaceuticals Inc. | Reduce Risk of Ototoxicity Associated with Cisplatin | 09/20/2022 | 92:12 - Antidotes | 5P/O | |
| Skysona® | Elivaldogene autotemcel | Bluebird bio, Inc | neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD) | 09/16/2022 | 26:12 - Gene Therapy | ||
| Terlivaz® | Terlipressin | Mallinckrodt | Hepatorenal Syndrome (HRS) | 09/14/2022 | 68:28 - Pituitary | 1P/O | |
| Rolvedon® | Eflapegrastim-xnst | Spectrum Pharms | Chemotherapy-induced neutropenia | 09/09/2022 | 20:16 - Hematopoietic Agents | BLA | |
| Sotyktu® | Deucravacitinib | Bristol Myers Squibb | plaque psoriasis | 09/09/2022 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 1S | |
| Daxxify® | daxibotulinumtoxinA-lanm | Revance Therapeutics, INC. | glabellar lines | 09/07/2022 | 92:92 - Other Miscellaneous Therapeutic Agents; 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous | BLA | |
| Spevigo® | spesolimab-sbzo | Boehringer Ingelheim Pharmaceuticals INC | generalized pustular psoriasis (GPP) flares in adults | 09/01/2022 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | BLA/O | |
| Xenpozyme® | olipudase alfa-rpcp | Genzyme Corp | non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) | 08/31/2022 | 44:00 - Enzymes | BLA/O | |
| Auvelity® | dextromethorphan and bupropion | Axsome Therapeutics, Inc | major depressive disorder | 08/18/2022 | 28:16.04.92 - Antidepressants, Miscellaneous | 3/4P | |
| Zynteglo® | betibeglogene autotemcel | bluebird bio, Inc | beta-thalassemia | 08/17/2022 | 26:12 - Gene Therapy | ||
| Zoryve® | roflumilast | Arcutis | plaque psoriasis | 07/29/2022 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 3S | |
| Amvuttra® | vutrisiran | Alnylam Pharmaceuticals | hereditary transthyretin-mediated (hATTR) amyloidosis | 06/13/2022 | 92:92 - Other Miscellaneous Therapeutic Agents | 1S/O | |
| Riabni® | rituximab-arrx | Amgen | Rheumatoid Arthritis | 06/06/2022 | 10:00 - Antineoplastic Agents; 92:36 - Disease-modifying Antirheumatic Drugs | ||
| Fylnetra® | pegfilgrastim-pbbk | Amneal Pharmaceuticals, Inc | neutropenia | 05/26/2022 | 20:16 - Hematopoietic Agents | ||
| Vtama® | tapinarof | Dermavant Sciences | Plaque Psoriasis | 05/23/2022 | 84:06.92 - Anti-inflammatory Agents, Miscellaneous | 1S | |
| TPOXX | Tecovirimat | SIGA | treatment of smallpox | 05/19/2022 | 8:18.92 - Antivirals, Miscellaneous | 3S/O | |
| Mounjaro® | tirzepatide | Eli Lilly and Co. | type 2 diabetes | 05/13/2022 | 68:20.06 - Incretin Mimetics | 1P | |
| Voquezna® | vonoprazan; amoxicillin; clarithromycin | Phathom Pharmaceuticals | H. pylori Infection | 05/03/2022 | 56:28.18 - Potassium-competitive Acid Blockers; 8:12.16.08 - Aminopenicillins; 8:12.12.92 - Other Macrolides | 1/4P | |
| Camzyos® | mavacamten | MyoKardia | obstructive hypertrophic cardiomyopathy | 04/28/2022 | 24:04.92 - Cardiac Drugs, Miscellaneous | 1S/O | |
| Vivjoa® | oteseconazole | Mycovia | vulvovaginal candidiasis (RVVC) | 04/26/2022 | 8:14.08 - Azoles | 1P | |
| Alymsys® | bevacizumab-maly | Amneal | metastatic colorectal cancer | 04/13/2022 | 10:00 - Antineoplastic Agents | BLA | |
| Yescarta® | axicabtagene ciloleucel | Kite | large B-cell lymphoma | 04/01/2022 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | ||
| Tlando® | testosterone undecanoate | Antares | testosterone replacement therapy | 03/28/2022 | 68:08 - Androgens | 3S | |
| Pluvicto® | lutetium Lu 177 vipivotide tetraxetan | Advanced Accelerator Applications/Novartis | metastatic prostate cancer | 03/23/2022 | 10:00 - Antineoplastic Agents; 78:00 - Radioactive Agents | 1P | |
| Xelstrym® | dextroamphetamine | Noven | ADHD | 03/22/2022 | 28:20.04 - Amphetamines | 3S | |
| Hyftor® | sirolimus topical gel | Nobelpharma America, | facial angiofibroma associated with tuberous sclerosis | 03/22/2022 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 3P/O | |
| Opdualag® | nivolumab and relatlimab-rmbw | Bristol Myers Squibb | metastatic melanoma | 03/18/2022 | 10:00 - Antineoplastic Agents | BLA/O | |
| Ztalmy® | ganaxolone | Marinus Pharmaceuticals | seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder | 03/18/2022 | 28:12.92 - Anticonvulsants, Miscellaneous | 1P/O | |
| Adlarity® | donepezil hydrochloride | Corium | Alzheimer's disease | 03/11/2022 | 12:04 - Parasympathomimetic (Cholinergic) Agents | 3S | |
| Vonjo® | pacritinib | CTI Biopharma | cytopenic myelofibrosis | 02/28/2022 | 10:00 - Antineoplastic Agents | 1P/O | |
| Carvykti® | ciltacabtagene autoleucel | Janssen | multiple myeloma | 02/28/2022 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | ||
| Releuko® | filgrastim-ayow | Amneal | neutropenia | 02/25/2022 | 20:16 - Hematopoietic Agents | 351(k) | |
| Megatope® | iodinated i-131 albumin | Iso-Tex Diagnostics | diagonostic radiopharmaceutical | 02/24/2022 | 36:68 - Roentgenography | ||
| Pyrukynd® | mitapivat | Agios | hemolytic anemia in adults with pyruvate kinase (PK) deficiency | 02/17/2022 | 20:92 - Blood Formation, Coagulation, and Thrombosis Agents; Miscellaneous | 1P/O | |
| bebtelovimab | bebtelovimab | Eli Lilly | COVID-19 | 02/11/2022 | 8:18.24 - Monoclonal Antibodies | EUA | |
| Regkirona® | Regdanvimab | Celltrion Healthcare | COVID-19 | 02/11/2022 | 8:18.24 - Monoclonal Antibodies | ||
| Fleqsuvy® | baclofen oral suspension | Azurity | spasticity | 02/04/2022 | 12:20.12 - GABA-derivative Skeletal Muscle Relaxants | 3S | |
| Enjaymo® | Sutimlimab-jome | Bioverativ | cold agglutinin disease | 02/04/2022 | 20:92 - Blood Formation, Coagulation, and Thrombosis Agents; Miscellaneous | BLA | |
| Vabysmo® | faricimab-svoa | Genentech | macular degeneration/macular edema | 01/28/2022 | 52:56 - Vascular Endothelial Growth Factor Antagonists | BLA | |
| Kimmtrak® | tebentafusp-tebn | Immunocore | uveal melanoma | 01/25/2022 | 10:00 - Antineoplastic Agents | BLA | |
| Cibinqo® | abrocitinib | Pfizer | atopic dermatitis | 01/14/2022 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 1P | |
| Quviviq® | daridorexant | Idorsia | Insomnia | 01/07/2022 | 28:24.40 - Orexin Receptor Antagonists | 1S | |
| Recorlev® | levoketoconazole | Strongbridge Dublin | Cushing's Disease | 12/30/2021 | 92:92 - Other Miscellaneous Therapeutic Agents | 2S/O | |
| Adbry® | tralokinumab-ldrm | LEO Pharma | atopic dermatitis | 12/27/2021 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | BLA | |
| Molnupiravir | Molnupiravir | Merck Sharp Dohme | treatment of COVID-19 | 12/23/2021 | 8:18.32 - Nucleosides and Nucleotides | EUA | |
| Paxlovid® | nirmatrelvir and ritonavir | Pfizer | treatment of COVID-19 | 12/22/2021 | 8:18.92 - Antivirals, Miscellaneous | EUA | |
| Leqvio® | inclisiran | Novartis | heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) | 12/22/2021 | 24:06.92 - Antilipemic Agents, Miscellaneous | 1S | |
| Illuccix | gallium Ga 68 gozetotide | Telix | prostate cancer imaging | 12/20/2021 | 36:68 - Roentgenography | 3/4S | |
| Tezspire | tezepelumab-ekko | AZ and Amgen | add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe asthma | 12/17/2021 | 48:92 - Respiratory Tract Agents, Miscellaneous | BLA | |
| Vyvgart® | efgartigimod alfa-fcab | argenx | treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive | 12/17/2021 | 92:20 - Immunomodulatory Agents | BLA | |
| tixagevimab/cilgavimab | tixagevimab/cilgavimab | Astra Zeneca | treatment of COVID-19 | 12/08/2021 | 8:18.24 - Monoclonal Antibodies | EUA | |
| Cytalux® | pafolacianine | On Target Lab | optical imaging agent | 11/29/2021 | 36:68 - Roentgenography | 1O | |
| Fyarro® | sirolimus protein-bound particles | Aadi Bioscience | treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). | 11/23/2021 | 10:00 - Antineoplastic Agents | 5P/O | |
| Livtencity® | maribavir | Takeda | post-transplant CMV infection | 11/23/2021 | 8:18.92 - Antivirals, Miscellaneous | 1P/O | |
| Voxzogo® | vosoritide | Biomarin | increase linear growth in patients with achondroplasia | 11/19/2021 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | |
| Besremi® | ropeginterferon alfa-2b-njft | Pharmaessentia Corp | polycythemia vera | 11/12/2021 | 10:00 - Antineoplastic Agents | BLA | |
| Scemblix® | asciminib | Novartis | chronic myeloid leukemia | 10/29/2021 | 10:00 - Antineoplastic Agents | 1P/O | |
| Tavneos® | avacopan | ChemoCentryx | anca-associated vasculitis | 10/11/2021 | 92:32 - Complement Inhibitors | CUO | |
| Rethymic® | allogeneic processed thymus tissue–agdc | Enzyvant | For immune reconstitution in pediatric patients with congenital athymia | 10/08/2021 | 26:00 - Cellular Therapy | BLA | |
| Livmarli® | maralixibat | Mirum | cholestatic pruritus secodary to alagille syndrome | 09/29/2021 | 56:92 - GI Drugs, Misc | 1P/O | |
| Qulipta® | atogepant | Abbvie | migraine headaches | 09/28/2021 | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists | 1P/O | |
| Opzelura® | ruxolitinib | Incyte | atopic dermatitis | 09/21/2021 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 10P | |
| Tivdak® | tisotumab vedotin-tftv | Seagen | cervical cancer | 09/20/2021 | 10:00 - Antineoplastic Agents | BLA | |
| Byooviz® | ranibizumab-nuna | Samsung Bioepis | macular degeneration | 09/17/2021 | 52:92 - EENT Drugs, Miscellaneous | BLA | |
| Exkivity® | mobocertinib succinate | Takeda | non-small cell lung cancer | 09/15/2021 | 10:00 - Antineoplastic Agents | 1P/O | |
| Skytrofa® | lonapegsomatropin-tcgd | Ascendis Pharma | pediatric growth hormone deficiency | 08/25/2021 | 68:28 - Pituitary | BLA | |
| Korsuva® | difelikefalin | Cara Therap | pruritus associated with chronic kidney disease | 08/23/2021 | 84:92 - Skin and Mucous Membrane Agents, Misc | 1P/O | |
| Welireg® | belzutifan | Merck Sharp Dohme | von Hippel-Lindau disease | 08/13/2021 | 10:00 - Antineoplastic Agents | 1P/O | |
| TicoVac® | tick-borne encephalitis vaccine | Pfizer | tick-borne encephalitis | 08/13/2021 | 80:12 - Vaccines | BLA | |
| Nexviazyme® | avalglucosidase alfa-ngpt | Genzyme Corp | late-onset pompe disease | 08/06/2021 | 44:00 - Enzymes | Orphan | |
| Saphnelo® | anifrolumab-fnia | Astra Zeneca | systemic lupus erythematosus | 07/30/2021 | 92:44 - Immunosuppressive Agents | BLA | |
| Bylvay® | odevixibat | Albireo Pharma Inc | pruritus in patients with progressive familial intrahepatic cholestasis | 07/20/2021 | 56:92 - GI Drugs, Miscellaneous | 1P/O | |
| Fexinidazole | fexinidazole | N/A | human African trypanosomiasi | 07/16/2021 | 8:30.92 - Miscellaneous Antiprotozoals | 1P/O | |
| Rezurock® | belumosudil | Kadmon Pharma LLC | graft-versus-host disease | 07/16/2021 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | |
| Kerendia® | finerenone | Bayer | chronic kidney disease | 07/09/2021 | 24:32.20 - Mineralocorticoid (Aldosterone) Receptor Antagonists | 1P/O | |
| Rylaze® | asparaginase erwinia chrysanthemi (recombinant)-rywn | Jazz Pharms | acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) | 06/30/2021 | 10:00 - Antineoplastic Agents | BLA | |
| Aduhelm® | aducanumab-avwa | Biogen Inc | Alzheimer's disease | 06/07/2021 | 28:92 - Central Nervous System Agents, Miscellaneous | BLA | |
| Tembexa® | brincidofovir | Chimerix Inc | smallpox | 06/04/2021 | 8:18.32 - Nucleosides and Nucleotides | 2P/O | |
| Ryplazim® | plasminogen, human-tmvh | ProMetic Biotherapeutics Inc. | plasminogen deficiency | 06/04/2021 | 16:00 - Blood Derivatives | BLA | |
| Brexafemme® | ibrexafungerp | Scynexis, Inc | vulvovaginal candidiasis | 06/01/2021 | 8:14.92 - Miscellaneous Antifungals | 1S | |
| Lybalvi® | olanzapine; samidorphan | Alkermes Inc | Schizophrenia/Bipolar I | 05/28/2021 | 28:16.08.04 - Atypical Antipsychotics | 1S | |
| Truseltiq® | infigratinib | Qed Therapeutics Inc | cholangiocarcinoma | 05/28/2021 | 10:00 - Antineoplastic Agents | 1P/O | |
| Lumakras® | sotorasib | Amgen Inc | lung cancer | 05/28/2021 | 10:00 - Antineoplastic Agents | 1P/O | |
| sotrovimab | sotrovimab | GlaxoSmithKline | COVID-19 | 05/26/2021 | 8:18.24 - Monoclonal Antibodies | EUA | |
| Myfembree® | relugolix; estradiol; norethindrone | Myovant Sciences | menstrual bleeding | 05/26/2021 | 68:18.04 - Antigonadotropins | 1S/O | |
| Pylarify® | Piflufolastat F 18 | Progenics Pharms Inc | diagnostic agent | 05/26/2021 | 78:00 - Radioactive Agents | 1P | |
| Camcevi® | leuprolide mesylate | Forsee Pharmaceuticals | prostate cancer | 05/25/2021 | 68:18.08 - Gonadotropins | 2S | |
| Rybrevant® | amivantamab-vmjw | Janssen Biotech | lung cancer | 05/21/2021 | 10:00 - Antineoplastic Agents | BLA | |
| Empaveli® | pegcetacoplan | Apellis Pharmaceuticals Inc | paroxysmal nocturnal hemoglobinuria | 05/14/2021 | 92:32 - Complement Inhibitors | 1S/O | |
| Zynrelef Kit® | bupivacaine; meloxicam | Heron Therapeutics, Inc. | postsurgical analgesia | 05/12/2021 | 72:00 - Local Anesthetics | 4P | |
| Zynlonta® | loncastuximab tesirine-lpyl | ADC Therapeutics SA | diffuse large b-cell lymphoma | 04/23/2021 | 10:00 - Antineoplastic Agents | BLA | |
| Jemperli® | dostarlimab-gxly | Glaxo-Smithkline | endometrial cancer | 04/22/2021 | 10:00 - Antineoplastic Agents | BLA | |
| Qelbree® | viloxazine | Supernus Pharms | ADHD | 04/02/2021 | 28:92 - Central Nervous System Agents, Miscellaneous | 1S/O | |
| Abecma® | idecabtagene vicleucel | Bristol Myers Squibb | multiple myeloma | 03/26/2021 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | BLA | |
| Zegalogue® | dasiglucagon | Zealand Pharma | severe hypoglycemia | 03/22/2021 | 68:22.12 - Glycogenolytic Agents | 1S/O | |
| Ponvory® | ponesimod | Janssen | multiple sclerosis | 03/18/2021 | 92:20 - Immunomodulatory Agents | 1S/O | |
| Fotivda® | tivozanib | Aveo Pharmaceuticals Inc | Renal Cell Carcinoma | 03/10/2021 | 10:00 - Antineoplastic Agents | 1S/O | |
| Azstarys® | serdexmethylphenidate; dexmethylphenidate | Commcave Therapeutics SA | ADHD | 03/02/2021 | 28:20.32 - Respiratory and CNS Stimulants | 1S/O | |
| COVID-19 Vaccine (Janssen) | SARS-CoV-2 (COVID-19) vaccine, Adenovirus Vector | Janssen Biotech, Inc. | COVID-19 | 02/27/2021 | 80:12 - Vaccines | EUA | |
| Nulibry® | fosdenopterin | Origin Biosciences Inc | molybdenum cofactor deficiency (MoCD) type a | 02/26/2021 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | |
| Pepaxto® | melphalan flufenamide | Oncopeptides AB | relapsed or refractory multiple myeloma | 02/26/2021 | 10:00 - Antineoplastic Agents | 1P/O | |
| Amondys 45® | casimersen | Sarepta Therapeutics, Inc. | Duchenne Muscular Dystrophy | 02/25/2021 | 92:18 - Antisense Oligonucleotides | 1P/O | |
| Cosela® | trilaciclib | G1 Therapeutics, Inc. | chemotherapy-induced myelosuppression | 02/12/2021 | 92:56 - Protective Agents | 1P/O | |
| Evkeeza® | evinacumab-dgnb | Regeneron Pharmaceuticals | homozygous familial hypercholesterolemia | 02/11/2021 | 24:06.92 - Antilipemic Agents, Miscellaneous | BLA | |
| bamlanivimab; etesevimab | bamlanivimab; etesevimab | Eli Lilly and Company | COVID-19 | 02/09/2021 | 8:18.24 - Monoclonal Antibodies | EUA | |
| Ukoniq® | umbralisib | TG Therapeutics, Inc. | marginal zone lymphoma | 02/05/2021 | 10:00 - Antineoplastic Agents | 1P/O | |
| Breyanzi® | lisocabtagene maraleucel | Juno Therapeutics, Inc | non-Hodgkin lymphoma | 02/05/2021 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | BLA | |
| Tepmetko® | tepotinib | Emd Serono, Inc. | non-small cell lung cancer | 02/03/2021 | 10:00 - Antineoplastic Agents | 1P/O | |
| Lupkynis® | voclosporin | Aurinia Pharmaceuticals, Inc. | lupus nephritis | 01/22/2021 | 92:44 - Immunosuppressive Agents | 1P/O | |
| Cabenuva® | cabotegravir and rilpivirine | Viiv Healthcare | HIV | 01/21/2021 | 8:18.08.12 - HIV Integrase Inhibitor | 1P/O | |
| Vocabria® | cabotegravir | Viiv Healthcare | HIV | 01/21/2021 | 8:18.08.12 - HIV Integrase Inhibitors | 1P/O | |
| Verquvo® | vericiguat | Merck Sharp Dohme | heart failure | 01/19/2021 | 24:12.92 - Vasodilating Agents, Miscellaneous | 1P/O | |
| Gemtesa® | vibegron | Urovant Sciences | overactive bladder | 12/23/2020 | 86:12.08.12 - Selective beta-3 Adrenergic Agonists | 1S/O | |
| Ebanga® | ansuvimab-zykl | Ridgeback Biotherapeutics | zaire ebolavirus infection | 12/21/2020 | 8:18.24 - Monoclonal Antibodies | Orphan | |
| Orgovyx® | relugolix | Myovant Sciences | prostate cancer | 12/18/2020 | 68:18.04 - Antigonadotropins | 1P/O | |
| COVID-19 Vaccine (Moderna) | SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein | Moderna | COVID-19 | 12/18/2020 | 80:12 - Vaccines | EUA | |
| Margenza® | margetuximab-cmkb | MacroGenics | HER2 positive breast cancer | 12/16/2020 | 10:00 - Antineoplastic Agents | BLA | |
| Klisyri® | tirbanibulin | Athenex | actinic keratosis | 12/14/2020 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 1S/O | |
| COVID-19 Vaccine (Pfizer-BioNTech) | SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein | Pfizer-BioNTech | COVID-19 | 12/11/2020 | 80:12 - Vaccines | EUA | |
| Orladeyo® | berotralstat | Biocryst | hereditary angioedema | 12/03/2020 | 92:32 - Complement Inhibitors | 1S/O | |
| Thyquidity® | levothyroxine sodium | Reguliance | hypothyroidism; pituitary thyrotropin suppression | 11/30/2020 | 68:36.04 - Thyroid Agents | 5S | |
| Imcivree® | setmelanotide | Rhythm | obesity due to three rare genetic conditions: POMC, PCSK1, LEPR | 11/27/2020 | 28:20.08.92 - Anorexigenic Agents, Miscellaneous | 1P/O | |
| Danyelza® | naxitamab-gqgk | Y-Mabs | relapsed or refractory high-risk neuroblastoma in the bone or bone marrow | 11/25/2020 | 10:00 - Antineoplastic Agents | 1P/O | |
| Oxlumo® | lumasiran | Alnylam | primary hyperoxaluria type 1 (PH1) | 11/23/2020 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | |
| Zokinvy® | lonafarnib | Eiger | Hutchinson-Gilford progeria syndrome and progeroid laminopathies | 11/20/2020 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | |
| casirivimab; imdevimab | Regeneron | COVID-19 | 11/20/2020 | 8:18.24 - Monoclonal Antibodies | 1P/O | ||
| Sutab® | magnesium sulfate; potassium chloride; sodium sulfate | Braintree | colonoscopy preparation | 11/10/2020 | 56:12 - Cathartics and Laxatives | 3S | |
| bamlanivimab | Eli Lilly & Co. | COVID-19 | 11/10/2020 | 8:18.24 - Monoclonal Antibodies | |||
| Sesquient® | fosphenytoin sodium | Sedor | generalized tonic-clonic status epilepticus | 11/05/2020 | 28:12.12 - Hydantoins | 5S | |
| Bronchitol® | mannitol | Chiesi | cystic fibrosis | 10/30/2020 | 48:92 - Respiratory Tract Agents, Misc | 10S/O | |
| Eysuvis® | loteprednol etabonate | Kala | short-term treatment of dry eye disease | 10/26/2020 | 52:08.08 - Corticosteroids | 5S | |
| Veklury® | remdesivir | Gilead | COVID-19 | 10/22/2020 | 8:18.32 - Nucleosides and Nucleotides | 1P | |
| Inmazeb® | atoltivimab; maftivimab; odesivimab-ebgn | Regeneron | Zaire ebolavirus | 10/14/2020 | 8:18.24 - Monoclonal Antibodies | BAE | |
| Alkindi® Sprinkle | hydrocortisone | Diurnal | replacement therapy in pediatric patients with adrenocortical insufficiency | 09/29/2020 | 68:04 - Adrenals | 3S | |
| Xeljanz® Oral Solution | tofacitinib citrate | Pfizer | RA, PsA, UC, JIA | 09/25/2020 | 92:36 - Disease-modifying Antirheumatic Drugs | 3P | |
| Gavreto® | pralsetinib | Blueprint Medicines | metastatic rearranged during transfection (RET) fusion- positive nonsmall cell lung cancer (NSCLC) | 09/04/2020 | 10:00 - Antineoplastic Agents | 1P/O | |
| Detectnet® | copper CU-64 dotatate | Radiomedix | with PET for localization of somatostatin receptor positive neuroendocrine tumors (NETs) | 09/03/2020 | 36:68 - Roentgenographic and Other Imaging Agents | 1P/O | |
| Onureg® | azacitidine | Celgene | acute myeloid leukemia | 09/01/2020 | 10:00 - Antineoplastic Agents | 3P/O | |
| Qdolo® | tramadol hydrochloride | Athena | pain | 09/01/2020 | 28:08.08 - Opiate Agonists | 3S | |
| Xaracoll® | bupivacaine hydrochloride | Innocoll | postsurgical analgesia for up to 24 hours following open inguinal hernia repair | 08/28/2020 | 72:00 - Local Anesthetics | 3S | |
| Sogroya® | somapacitan-beco | Novo Nordisk | growth hormone deficiency | 08/28/2020 | 68:28 - Pituitary | BLA/O | |
| Winlevi® | clascoterone | Cassiopea | acne vulgaris | 08/26/2020 | 84:92 - Skin and Mucous Membrane Agents, Misc | 1S | |
| Kesimpta® | ofatumumab | Novartis | relapsing forms of multiple sclerosis (MS) | 08/20/2020 | 92:20 - Immunomodulatory Agents | 8 | |
| Cystadrops® | cysteamine hydrochloride | Recordati | corneal cystine crystal deposits in adults and children with cystinosis | 08/19/2020 | 52:92 - EENT Drugs, Misc | 5S | |
| Enspryng® | satralizumab-mwge | Genentech | neuromyelitis optica spectrum disorder (NMOSD) | 08/14/2020 | 92:20 - Immunomodulatory Agents | 8M | |
| Viltepso® | viltolarsen | NS Pharma | Duchenne muscular dystrophy (DMD) | 08/12/2020 | 92:18 - Antisense Oligonucleotides | 1P | |
| Olinvyk® | oliceridine | Trevena | acute pain | 08/07/2020 | 28:08.08 - Opiate Agonists | 1S | |
| Evrysdi® | risdiplam | Genentech | spinal muscular atrophy (SMA) | 08/07/2020 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | |
| Lampit® | nifurtimox | Bayer | Chagas disease (American Trypanosomiasis) | 08/06/2020 | 8:30.92 - Antiprotozoals, Misc | 1P | |
| Blenrep® | belantamab mafodotin-blmf | GlaxoSmithKline | relapsed or refractory multiple myeloma | 08/05/2020 | 10:00 - Antineoplastic Agents | ||
| Monjuvi® | tafasitamab-cxix | Morphosys | diffuse large B-cell lymphoma (DLBCL) | 07/31/2020 | 10:00 - Antineoplastic Agents | 7L | |
| Xeglyze® | abametapir | Dr. Reddy's | head lice | 07/24/2020 | 84:04.12 - Scabicides and Pediculicides | 1S | |
| Tecartus® | brexucabtagene autoleucel | Kite Pharma | relapsed/refractory mantle cell lymphoma (r/r MCL) | 07/24/2020 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | 7 | |
| Breztri Aerosphere® | budesonide; formoterol fumarate; glycopyrrolate | AstraZeneca | chronic obstructive pulmonary disease (COPD) | 07/23/2020 | 68:04 - Adrenals; 12:12.08.12 - Selective beta-2-Adrenergic Agonists; 12:08.08 - Antimuscarinics/Antispasmodics | 5S | |
| Xywav® (CIII) | calcium; magnesium; potassium; sodium oxybates | Jazz | cataplexy or excessive daytime sleepiness (EDS) | 07/21/2020 | 28:92 - Central Nervous System Agents, Misc | 1P | |
| Wynzora® | calcipotriene; betamethasone dipropionate | MC2 Therapeutics | plaque psoriasis | 07/20/2020 | 84:92 - Skin and Mucous Membrane Agents, Misc; 84:06.08 - Corticosteroids | 5S | |
| Upneeq® | oxymetazoline hydrochloride | RVL Pharma | acquired blepharoptosis | 07/08/2020 | 52:32 - Vasoconstrictors | S | |
| Inqovi® | cedazuridine; decitabine | Astex | myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) | 07/07/2020 | 10:00 - Antineoplastic Agents | 1P | |
| Qwo® | collagenase clostridium histolyticum-aaes | Endo | moderate to severe cellulite | 07/06/2020 | 44:00 - Enzymes | ||
| Hulio® | adalimumab-fkjp | Mylan | RA, JIA, PsA, AS, CD, UC, Ps | 07/06/2020 | 92:20 - Immunomodulatory Agents | 7P/O | |
| Byfavo® | remimazolam | Cosmo | induction and maintenance of procedural sedation | 07/02/2020 | 28:24.08 - Benzodiazepines | 1P | |
| Tralement® | trace elements 4 (cupric sulfate; manganese sulfate; selenious acid; zinc sulfate) | American Reagent | parenteral nutrition | 07/02/2020 | 40:12 - Replacement Preparations | 4S | |
| Rukobia® | fostemsavir tromethamine | Viiv | HIV-1 infection | 07/02/2020 | 8:18.08.04 - HIV Entry and Fusion Inhibitors | 1P | |
| Dojolvi® | triheptanoin | Ultragenyx | caloric and fatty acid replacement with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD) | 06/30/2020 | 40:20 - Caloric Agents | 1S | |
| Phesgo® | pertuzumab; trastuzumab; hyaluronidase-zzxf | Genentech | HER2-positive breast cancer | 06/29/2020 | 10:00 - Antineoplastic Agents | BLT | |
| Mycapssa® | octreotide | Chiasma | acromegaly | 06/26/2020 | 68:29.04 - Somatostatin Agonists | 5S/O | |
| Fintepla® | fenfluramine | Zogenix | seizures associated with Dravet syndrome | 06/25/2020 | 28:12.92 - Anticonvulsants, Misc | 3P | |
| Gimoti® | metoclopramide hydrochloride | Evoke | acute and recurrent diabetic gastroparesis | 06/19/2020 | 56:32 - Prokinetic Agents | 3/4S | |
| Zepzelca® | lurbinectedin | Pharma Mar | metastatic small cell lung cancer (SCLC) | 06/15/2020 | 10:00 - Antineoplastic Agents | 1P/O | |
| Lyumjev® | insulin lispro-aabc | Eli Lilly | diabetes mellitus | 06/15/2020 | 68:20.08.04 - Rapid-acting Insulins | ||
| Tivicay PD® | dolutegravir | Viiv | HIV-1 infection in pediatric patients | 06/12/2020 | 8:18.08.12 - HIV Integrase Inhibitors | 3P | |
| Uplizna® | inebilizumab-cdon | Viela Bio | neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive | 06/11/2020 | 92:20 - Immunomodulatory Agents | ||
| Semglee® | insulin glargine | Mylan | diabetes mellitus | 06/11/2020 | 68:20.08.16 - Long-acting Insulins | 6P/O | |
| Nyvepria® | pegfilgrastim-apgf | Hospira | febrile neutropenia | 06/10/2020 | 20:16 - Hematopoietic Agents | 6P/O | |
| Oriahnn® | elagolix; estradiol; norethindrone acetate | Abbvie | heavy menstrual bleeding associated with uterine leiomyomas (fibroids) | 05/29/2020 | 68:18.04 - Antigonadotropins; 68:16.04 - Estrogens; 68:32 - Progestins | 4S | |
| Tauvid® | flortaucipir F18 | Avid Radiopharms | PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) | 05/28/2020 | 36:68 - Roentgenographic and Other Imaging Agents | 1P | |
| Zilxi® | minocycline | Foamix | inflammatory lesions of rosacia | 05/28/2020 | 84:04.04 - Antibacterials | 5S | |
| Artesunate | artesunate | Amivas | acute malarial infection | 05/27/2020 | 8:30.08 - Antimalarials | 1P | |
| VESIcare LS® | solifenacin succinate | Astellas | neurogenic detrusor overactivity (bladder dysfunction) | 05/26/2020 | 86:12.04 - Antimuscarinics | 3S | |
| Phexxi® | lactic acid; citric acid; potassium bitartrate | Evofem | contraception | 05/22/2020 | 32:00 - Nonhormonal Contraceptives | 3S | |
| Kynmobi® | apomorphine hydrochloride | Sunovion | acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease | 05/21/2020 | 28:36.20.08 - Nonergot-derivative Dopamine Receptor Agonists | 3S | |
| Cerianna® | fluoroestradiol F18 | Zionexa | PET imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer | 05/20/2020 | 36:68 - Roentgenographic and Other Imaging Agents | 1S | |
| Ferriprox® | deferiprone | Apopharma | transfusional iron overload due to thalassemia syndromes | 05/19/2020 | 64:00 - Heavy Metal Antagonists | 5S | |
| Impeklo® | clobetasol propionate | Mylan | inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses | 05/19/2020 | 84:06.08 - Corticosteroids | 5S | |
| Qinlock® | ripretinib | Deciphera | gastrointestinal stromal tumor (GIST) (fourth-line treatment) | 05/15/2020 | 10:00 - Antineoplastic Agents | 1S | |
| Retevmo® | selpercatinib | Loxo Oncology | RET fusion-positive non-small cell lung cancer (NSCLC) or thyroid cancer; RET-mutant medullary thyroid cancer (MTC) | 05/08/2020 | 10:00 - Antineoplastic Agents | 1P | |
| Tabrecta® | capmatinib | Novartis | metastatic non-small cell lung cancer (NSCLC) (with MET exon 14 skipping mutation) | 05/06/2020 | 10:00 - Antineoplastic Agents | 1P | |
| Elyxyb® | celecoxib | Dr Reddy's | acute migraine headaches | 05/05/2020 | 28:08.04.08 - Cyclooxygenase-2 (COX-2) Inhibitors | 3S | |
| Fensolvi® | leuprolide acetate | Tolmar | central precocious puberty | 05/01/2020 | 68:18.08 - Gonadotropins | 10S | |
| Darzalex Faspro® | daratumumab; hyaluronidase-fihj | Janssen | multiple myeloma | 05/01/2020 | 10:00 - Antineoplastic Agents | 5P/O | |
| Veklury® | remdesivir | Gilead | COVID-19 | 05/01/2020 | 8:18.32 - Nucleosides and Nucleotides | 5P/O | |
| Milprosa® | progesterone | Ferring | infertility | 04/29/2020 | 68:32 - Progestins | 3S | |
| Bafiertem™ | monomethyl fumarate | Banner Life Sciences | multiple sclerosis | 04/28/2020 | 92:20 - Immunomodulatory Agents | 2S | |
| Ongentys® | opicapone | Neurocrine | Parkinson's Disease | 04/24/2020 | 28:36.12 - Catechol-O-Methyltransferase (COMT) Inhibitors | 1S | |
| Trodelvy® | sacituzumab govitecan-hziy | Immunomedics | metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease | 04/22/2020 | 10:00 - Antineoplastic Agents | 4f | |
| Tukysa® | tucatinib | Seattle Genetics | unresectable or metastatic HER2-positive breast cancer | 04/17/2020 | 10:00 - Antineoplastic Agents | 1S | |
| Pemazyre® | pemigatinib | Incyte | previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion | 04/17/2020 | 10:00 - Antineoplastic Agents | 1S | |
| Emerphed® | ephedrine sulfate | Nexus | anesthesia-induced hypotension | 04/17/2020 | 12:12.12 - alpha- and beta-Adrenergic Agonists | 5S | |
| Jelmyto® | mitomycin | Urogen | low-grade upper tract urothelial cancer (LG-UTUC) | 04/15/2020 | 10:00 - Antineoplastic Agents | 5S | |
| Koselugo® | selumetinib | AstraZeneca | neurofibromatosis type 1 (NF1) | 04/10/2020 | 10:00 - Antineoplastic Agents | 1P | |
| Zeposia® | ozanimod | Celgene | multiple sclerosis (MS) | 03/25/2020 | 92:20 - Immunomodulatory Agents | 1S | |
| Pulmotech MAA® | technetium Tc99m albumin aggregated | Cis Bio | lung scintigraphy; scintigraphy of peritoneovenous shunt | 03/20/2020 | 36:68 - Roentgenographic and Other Imaging Agents | 5S | |
| Fluorescien; Benoxinate | fluorescien sodium; benoxinate hydrochloride | Bausch | tonometry, gonioscopy | 03/09/2020 | 36:58 - Ocular Disorders; 52:16 - Local Anesthetics | 4S | |
| Isturisa® | osilodrostat | Novartis | Cushing's disease | 03/06/2020 | 92:92 - Other Miscellaneous Therapeutic Agents | 1S | |
| Durysta® | bimatoprost | Allergan | open angle glaucoma (OAG) or ocular hypertension (OHT) | 03/04/2020 | 52:40.28 - Prostaglandin Analogs | 3S | |
| Sarclisa® | isatuximab-irfc | Sanofi Aventis | multiple myeloma | 03/02/2020 | 10:00 - Antineoplastic Agents | ||
| Nurtec ODT® | rimegepant | Biohaven | migraine headaches | 02/27/2020 | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists | 1P | |
| Barhemsys® | amisulpride | Acacia | postoperative nausea and vomiting (PONV) | 02/26/2020 | 56:22.92 - Antiemetics, Misc | 1S | |
| Nexlizet® | bempedoic acid; ezetimibe | Esperion | heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease | 02/26/2020 | 24:06.92 - Antilipemic Agents, Misc; 24:06.05 - Cholesterol Absorption Inhibitors | 1/4S | |
| Nexletol® | bempedoic acid | Esperion | heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease | 02/21/2020 | 24:06.92 - Antilipemic Agents, Misc | 1S | |
| Vyepti® | eptinezumab-jjmr | Lundbeck | migraine headaches | 02/21/2020 | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists | 2P/O | |
| Anjeso® | meloxicam | Baudax Bio | moderate-to-severe pain | 02/20/2020 | 28:08.04.92 - Other Nonsteroidal Anti-inflammatory Agents | 3S | |
| Twirla® | ethinyl estradiol; levonorgestrel | Agile | birth control | 02/14/2020 | 68:12 - Contraceptives | 3S | |
| Procysbi® Granules | cysteamine bitartrate | Horizon | nephropathic cystinosis | 02/14/2020 | 92:92 - Other Misc Therapeutic Agents | 5S | |
| Pizensy® | lactitol monohydrate | Braintree | chronic idiopathic constipation (CIC) | 02/12/2020 | 56:12 - Cathartics and Laxatives | 1S | |
| Pemfexy® | pemetrexed | Eagle Pharms | recurrent, metastatic non-squamous, non-small cell lung cancer (NSCLC); malignant pleural mesothelioma | 02/08/2020 | 10:00 - Antineoplastic Agents | 5S | |
| Palforzia® | peanut (Arachis hypogaea) allergen powder-dnfp | Aimmune Therapeutics | mitigation of allergic reactions that may occur with accidental peanut exposure | 01/31/2020 | 80:02 - Allergenic Extracts | BEN | |
| Benfezia Pen® | octreotide | Sun Pharm | acromegaly; severe diarrhea/flushing episodes associated with metastatic carcinoid tumors; profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas) | 01/28/2020 | 68:29.04 - Somatostatin Agonists | 5S | |
| Trijardy XR® | empagliflozin; linagliptin; metformin | Boehringer Ingelheim | type 2 diabetes mellitus | 01/27/2020 | 68:20.18 - SGLT2 Inhibitors; 68:20.05 - DPP-4 Inhibitors; 68:20.04 - Biguanides | 4S | |
| Tazverik® | tazemetostat | Epizyme | metastatic or locally advanced epithelioid sarcoma not eligible for complete resection | 01/23/2020 | 10:00 - Antineoplastic Agents | 1P | |
| Tepezza® | teprotumumab-trbw | Horizon Therapeutics | thyroid eye disease | 01/21/2020 | 52:92 - EENT Drugs, Miscellaneous | 1O/P | |
| Monoferric® | ferric derisomaltose | Pharmacosmos | iron deficiency anemia | 01/16/2020 | 20:04.04 - Iron Preparations | 5S | |
| Rybelsus® | semaglutide | Novo Nordisk | diabetes mellitus | 01/16/2020 | 68:20.06 - Incretin Mimetics | 9S | |
| Numbrino® | cocaine | Cody Labs | local anesthesia | 01/10/2020 | 52:16 - Local Anesthetics | 7S | |
| Valtoco® | diazepam | Neurelis | seizures | 01/10/2020 | 28:12.08 - Benzodiazepines | 3S | |
| Ayvakit® | avapritinib | Blueprint Medicines | gastrointestinal stromal tumor (GIST) | 01/09/2020 | 10:00 - Antineoplastic Agents | 1P | |
| Ubrelvy® | ubrogepant | Allergan | migraine headaches | 12/23/2019 | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists | 1S | |
| Genosyl® | nitric oxide | Vero | hypoxic respiratory failure due to pulmonary hypertension | 12/20/2019 | 24:12.08 - Nitrates and Nitrites | 5S | |
| Caplyta® | lumateperone | Intra-cellular Therapies | schizophrenia | 12/20/2019 | 28:16.08.04 - Atypical Antipsychotics | 1S | |
| TissueBlue® | brilliant blue G (BBG) | Dutch Ophthalmic | selectively stain the internal limiting membrane | 12/20/2019 | 36:58 - Ocular Disorders | 1P | |
| Dayvigo® | lemborexant | Eisai | insomnia | 12/20/2019 | 28:24.92 - Anxiolytics, Sedatives, and Hypnotics; Misc | 1S | |
| Enhertu® | fam-trastuzumab deruxtecan-nxki | Daiichi Sankyo | HER2+ breast cancer | 12/20/2019 | 10:00 - Antineoplastic Agents | BLH | |
| Ervebo® | ebola Zaire vaccine, live | Merck | prevention of disease caused by Zaire ebolavirus | 12/19/2019 | 80:12 - Vaccines | ||
| Conjupri® | levamlodipine | CSPC Ouyi Pharma | hypertension | 12/19/2019 | 24:28.08 - Dihydropyridines | 2/3S | |
| Padcev® | enfortumab vedotin-ejfv | Astellas | advanced urothelial cancer | 12/18/2019 | 10:00 - Antineoplastic Agents | 1P/O | |
| Arazlo® | tazarotene | Dow | acne vulgaris | 12/18/2019 | 84:92 - Skin and Mucous Membrane Agents, Misc | 3S | |
| Nouress® | cysteine hydrochloride | Avadel | total parenteral nutrition | 12/13/2019 | 40:12 - Replacement Preparations | 5S | |
| Vyondys 53® | golodirsen | Sarepta | Duchenne muscular dystrophy (DMD) | 12/12/2019 | 92:18 - Antisense Oligonucleotides | 1P | |
| Avsola® | infliximab-axxq | Amgen | RA, JIA, PsA, AS, CD, pCD, UC, pUC, Ps | 12/06/2019 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents; 56:92 - GI Drugs, Misc; 84:92 - Skin and Mucous Membrane Agents, Misc | 1P/O | |
| Reditrex® | methotrexate | Cumberland | RA, pJIA, PA | 11/27/2019 | 92:20 - Immunomodulatory Agents | 5S | |
| Oxbryta® | voxelotor | Global Blood Therapeutics | sickle cell disease (SCD) | 11/25/2019 | 20:92 - Blood Formation, Coagulation, and Thrombosis Agents, Misc | 1S | |
| Exservan® | riluzole | Aquestive | amyotrophic lateral sclerosis (ALS) | 11/22/2019 | 28:92 - Central Nervous System Agents, Misc | 3S/O | |
| Xcopri® | cenobamate | SK Life | partial-onset seizures | 11/21/2019 | 28:12.92 - Anticonvulsants, Misc | 1S | |
| Givlaari® | givosiran | Alnylam | acute hepatic porphyria | 11/20/2019 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | |
| Abrilada® | adalimumab-afzb | Pfizer | RA, JIA, PsA, AS, CD, UC, Ps | 11/15/2019 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents; 56:92 - GI Drugs, Misc | 1P/O | |
| Adakveo® | crizanlizumab-tmca | Novartis | vaso-occlusive crisis assoc with sickle cell disease | 11/15/2019 | 20:92 - Blood Formation, Coagulation, and Thrombosis Agents, Misc | 1P/O | |
| Brukinsa® | zanubrutinib | Beigene | mantle cell lymphoma (MCL) | 11/14/2019 | 10:00 - Antineoplastic Agents | 1P/O | |
| Fetroja® | cefiderocol sulfate tosylate | Shionogi | complicated urinary tract infections (cUTI) | 11/14/2019 | 8:12.06.28 - Siderophore Cephalosporins (NEW) | 1P | |
| Reblozyl® | luspatercept-aamt | Celgene | anemia due to beta thalassemia | 11/08/2019 | 20:16 - Hematopoietic Agents | 1P/O | |
| ExEm Foam® | air polymer-type A | Giskit | sonohysterosalpingography | 11/07/2019 | 36:68 - Roentgenographic and Other Imaging Agents | 1S | |
| Absorica® | isotretinoin | Sun | severe recalcitrant nodular acne | 11/05/2019 | 84:92 - Skin and Mucous Membrane Agents, Misc | S | |
| Talicia® | omeprazole; amoxicillin; rifabutin | Redhill | Helicobacter pylori infection | 11/04/2019 | 56:28.92 - Antiulcer Agents and Acid Suppressants, Misc | 4P | |
| Ziextenzo® | pegfilgrastim-bmez | Sandoz | chemotherapy-induced neutropenia | 11/04/2019 | 20:16 - Hematopoietic Agents | 1P/O | |
| Vumerity® | diroximel fumarate | Alkermes | relapsing-remitting multiple sclerosis (MS) | 10/29/2019 | 92:20 - Immunomodulatory Agents | 2S | |
| Trikafta® | elexacaftor, tezacaftor, ivacaftor | Vertex | cystic fibrosis (CF) | 10/21/2019 | 48:14.04 - Cystic Fibrosis Transmembrane Conductance Regulator Correctors (1); 48:14.12 - Cystic Fibrosis Transmembrane Conductance Regulator Potentiators (2) | 1P/O | |
| Biorphen® | phenylephrine | Sintetica | clinically important hypotension resulting primarily from vasodilation during anesthesia | 10/21/2019 | 12:12.04 - alpha-Adrenergic Agonists | 5S | |
| Amzeeq® | minocycline topical foam | Foamix | acne vulgaris | 10/18/2019 | 84:04.04 - Antibacterials | 3S | |
| Reyvow® | lasmiditan | Eli Lilly | migraine headaches | 10/11/2019 | 28:32.28 - Selective Serotonin Agonists | 1S | |
| Secuado® | asenapine transdermal system | Hisamitsu | schizophrenia and bipolar disorder | 10/11/2019 | 28:16.08.04 - Atypical Antipsychotics | 3S | |
| Fluorodopa F18® | fluorodeoxyphenylalanine | Feinstein | positron emission tomography (PET) in diagnosing Parkinsonian Syndrome(PS) | 10/10/2019 | 36:68 - Roentgenographic and Other Imaging Agents | 1S | |
| Scenesse® | afamelanotide acetate | Clinuvel | prevent phototoxic reactions related to erythropoietic protoporphyria | 10/08/2019 | 84:92 - Skin and Mucous Membrane Agents, Misc | 1P/O | |
| Beovu® | brolucizumab-dbll | Novartis | wet age-related macular degeneration (AMD) | 10/07/2019 | 52:92 - EENT Drugs, Misc | 1( | |
| Quzyttir® | cetirizine | JDP | acute urticaria | 10/04/2019 | 4:08 - Second Generation Antihistamines | 3S | |
| Aklief® | trifarotene | Galderma | acne vulgaris | 10/04/2019 | 84:92 - Skin and Mucous Membrane Agents, Misc | 1S | |
| Bonsity® | teriparatide | Pfenex | osteoporosis | 10/04/2019 | 68:24.08 - Parathyroid Agents | 5S | |
| Hemady® | dexamethasone | Dexcel | multiple myeloma | 10/03/2019 | 68:04 - Adrenals | 1S/O | |
| Jynneos® | Smallpox and Monkeypox Vaccine Live | Bavarian Nordic | prevention of smallpox and monkeypox disease | 09/24/2019 | 80:12 - Vaccines | B1I | |
| Rybelsus® | semaglutide | Novo Nordisk | type 2 diabetes mellitus | 09/20/2019 | 68:20.06 - Incretin Mimetics | 3P | |
| Ozobax® | baclofen | Metacel | spasticity resulting from multiple sclerosis | 09/18/2019 | 12:20.12 - GABA-derivative Skeletal Muscle Relaxants | 3S | |
| Ibsrela® | tenapanor | Ardelyx | irritable bowel syndrome with constipation (IBS-C) | 09/12/2019 | 56:92 - GI Drugs, Misc | 1S | |
| Gvoke® | glucagon | Xeris | severe hypoglycemia | 09/10/2019 | 68:22.12 - Glycogenolytic Agents | 3S | |
| Nourianz® | istradefylline | Kyowa Kirin | add-on treatment for Parkinson's disease | 08/27/2019 | 28:92 - CNS Agents, Miscellaneous | 1S | |
| Gallium Ga-68 Dotatoc | gallium Ga-68 dotatoc | University of Iowa | use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) | 08/21/2019 | 36:68 - Roentgenographic and Other Imaging Agents | 1S | |
| Xenleta® | lefamulin acetate | Nabriva | community-acquired bacterial pneumonia (CABP) | 08/19/2019 | 8:12.28.26 - Pleuromutilins | 1P | |
| Inrebic® | fedratinib | Impact | intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) | 08/16/2019 | 10:00 - Antineoplastic Agents | 1S | |
| Rinvoq® | upadacitinib | Abbvie | rheumatoid arthritis | 08/16/2019 | 92:36 - Disease-modifying Antirheumatic Drugs | 1S | |
| Rozlytrek® | entrectinib | Genentech | cancers with NTRK gene fusion; metastatic ROS1+ non-small cell lung cancer | 08/15/2019 | 10:00 - Antineoplastic Agents | 1P | |
| Wakix® | pitolisant | Bioprojet | excessive daytime sleepiness (EDS) with narcolepsy | 08/14/2019 | 28:20.80 - Wakefulness-promoting Agents | 1S | |
| Pretomanid | pretomanid | Global Alliance for TB Drug Development | drug-resistant tuberculosis | 08/14/2019 | 8:16.04 - Antituberculosis Agents | 1P | |
| Turalio® | pexidartinib | Daiichi | symptomatic tenosynovial giant cell tumor (TGCT) | 08/02/2019 | 10:00 - Antioneoplastic Agents | 1P | |
| Nubeqa® | darolutamide | Bayer | non-metastatic castration-resistant prostate cancer | 07/30/2019 | 10:00 - Antioneoplastic Agents | 1P | |
| Angiomax RTU® | bivalirudin | Maia | acute ischemic complications of PCI; heparin-induced thrombocytopenia (HIT) in patients undergoing PCI or cardiac surgery | 07/25/2019 | 20:12.04.12 - Direct Thrombin Inhibitors | 5S | |
| Accrufer® | ferric maltol | Shield TX | iron deficiency | 07/25/2019 | 20:04.04 - Iron Preparations | 1S | |
| Baqsimi® | glucagon nasal powder | Eli Lilly | severe hypoglycemia | 07/24/2019 | 68:22.12 - Glycogenolytic Agents | 3S | |
| Ruxience® | rituximab-pvvr | Pfizer | non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) | 07/23/2019 | 10:00 - Antineoplastic Agents | 7P/O | |
| Hadlima® | adalimumab-bwwd | Samsung Bioepis | RA, JIA, PsA, AS, CD, UC, Ps | 07/23/2019 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents; 56:92 - GI Drugs, Misc | ||
| Drizalma Sprinkle® | duloxetine | Sun Pharma | major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), chronic musculoskeletal pain | 07/19/2019 | 28:16.04.16 - Selective Serotonin- and Norepinephrine-reuptake Inhibitors | 5S | |
| Recarbrio® | imipenem-cilastatin; relebactam | Merck | complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) | 07/16/2019 | 8:12.07.08 - Carbapenems | 1/4P | |
| Katerzia® | amlodipine oral suspension | Silvergate | hypertension; coronary artery disease (chronic stable angina, vasospastic angina) | 07/08/2019 | 24:28.08 - Dihydropyridines; 24:12.92 - Vasodilating Agents, Misc | 3S | |
| Xpovio® | selinexor | Karyopharm | relapsed refractory multiple myeloma | 07/03/2019 | 10:00 - Antineoplastic Agents | 1P | |
| Xembify® | immune globulin subcutaneous, human-klhw | Grifols | primary humoral immunodeficiency | 07/03/2019 | 80:04 - Antitoxins and Immune Globulins | U | |
| Thiola EC® | tiopronin | Mission | prevention of cystine stone formation with severe homozygous cystinuria | 06/28/2019 | 92:92 - Other Miscellaneous Therapeutic Agents | 3S | |
| Zirabev® | bevacizumab-bvzr | Pfizer | metastatic colorectal cancer; non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; in combination with other agents | 06/27/2019 | 10:00 - Antineoplastic Agents | 6P/O | |
| Vyleesi® | bremelanotide acetate | Amag | hypoactive sexual desire disorder (HSDD) | 06/21/2019 | 28:92 - Central Nervous System Agents, Misc | 1S | |
| Myxredlin® | insulin human; sodium chloride | Celerity | diabetes mellitus | 06/20/2019 | 68:20.08.08 - Short-acting Insulins | 5S | |
| Kanjinti® | trastuzumab-anns | Amgen | HER2 breast cancer; HER2 metastatic gastric or gastroesophageal junction adenocarcinoma | 06/13/2019 | 10:00 - Antineoplastic Agents | 6P/O | |
| Polivy® | polatuzumab vedotin-piiq | Genentech | diffuse large B-cell lymphoma (DLBCL) | 06/10/2019 | 10:00 - Antineoplastic Agents | 6L | |
| Piqray® | alpelisib | Novartis | HR+HER2-, PIK3CA-mutated, advanced or metastatic breast cancer | 05/24/2019 | 10:00 - Antineoplastic Agents | 1S | |
| Zolgensma® | onasemnogene abeparvovec-xioi | Novartis | spinal muscular atrophy (SMA) | 05/24/2019 | 26:12 - Gene Therapy | 5( | |
| Slynd® | drospirenone | Exeltis | oral contraception | 05/23/2019 | 68:12 - Contraceptives; 68:32 - Progestins | 2/3S | |
| Nayzilam® | midazolam nasal spray | Proximagen | intermittent, stereotypic episodes of frequent seizure activity | 05/17/2019 | 28:12.08 - Benzodiazepines | 3S/O | |
| Ruzurgi® | amifampridine | Jacobus | Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to 17 | 05/06/2019 | 92:92 - Other Miscellaneous Therapeutic Agents | 1O/P | |
| Vyndaqel® | tafamidis meglumine | FoldRx | cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) | 05/03/2019 | 24:04.92 - Cardiac Drugs, Misc | 1P | |
| Vyndamax® | tafamidis | FoldRx | cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) | 05/03/2019 | 24:04.92 - Cardiac Drugs, Misc | 1S | |
| Qternmet XR® | dapagliflozin; metformin; saxagliptin | AstraZeneca AB | type 2 diabetes mellitus | 05/02/2019 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.04 - Biguanides; 68:20.05 - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors | 4S | |
| Dengvaxia® | dengue tetravalent vaccine, live | Sanofi Pasteur | prevention of dengue disease caused by serotypes 1-4 in patients aged 9-16 | 05/01/2019 | 80:12 - Vaccines | B1I | |
| Zuragard® | isopropyl alcohol 70% | Zurex | skin preparation for surgery | 04/26/2019 | 84:04.92 - Local Anti-infectives, Misc | 5S | |
| Duobrii® | halobetasol propionate; tazarotene | Bausch | plaque psoriasis | 04/25/2019 | 84:06.08 - Corticosteroids; 84:92 - Skin and Mucous Membrane Agents, Misc | 5S | |
| Eticovo® | etanercept-ykro | Samsung Bioepsis | rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PsO) | 04/25/2019 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents (secondary) | ||
| Skyrizi® | risankizumab-rzaa | Abbvie | plaque psoriasis | 04/23/2019 | 84:92 - Skin and Mucous Membrane Agents, Misc | 4P/O | |
| Elcys® | cysteine hydrochloride | Exela | total parenteral nutrition | 04/16/2019 | 40:12 - Replacement Preparations | 5P | |
| Balversa® | erdafitinib | Janssen | locally advanced or metastatic bladder cancer | 04/12/2019 | 10:00 - Antineoplastic Agents | 1P | |
| Evenity® | romosozumab-aqqg | Amgen | osteoporosis | 04/09/2019 | 92:22 - Bone Anabolic Agents (new) | 4P/O | |
| Dovato® | dolutegravir; lamivudine | Viiv | HIV-1 infection | 04/08/2019 | 8:18.08.12 - HIV Integrase Inhibitors; 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors | 4P | |
| Asceniv® | immune globulin intravenous, human-slra | ADMA Biologics | primary humoral immunodeficiency | 04/01/2019 | 80:04 - Antitoxins and Immune Globulins | U | |
| Mavenclad® | cladribine | EMD Serono | relapsing forms of multiple sclerosis (MS) | 03/29/2019 | 92:44 - Immunosuppressive Agents | 3S | |
| Avaclyr® | acyclovir | Fera | acute herpetic keratitis (dendritic ulcers) with HSV-1 and HSV-2 infection | 03/29/2019 | 52:04.20 - Antivirals | 3S | |
| Duaklir® Pressair | aclidinium; formoterol | AstraZeneca | maintenance of COPD | 03/29/2019 | 12:08.08 - Antimuscarinics/Antispasmodics; 12:12.08.12 - Selective beta-2-Adrenergic Agonists | 4S | |
| Jatenzo® | testosterone undecanoate | Clarus | testosterone replacement therapy | 03/27/2019 | 68:08 - Androgens | 3S | |
| Mayzent® | siponimod | Novartis | multiple sclerosis | 03/26/2019 | 92:20 - Immunomodulatory Agents | 1S | |
| Sunosi® | solriamfetol | Jazz | daytime sleepiness assoc with narcolepsy or obstructive sleep apnea | 03/20/2019 | 28:20.80 - Wakefulness-promoting Agents | 1S | |
| Zulresso® | brexanolone | Sage | postpartum depression (PPD) | 03/19/2019 | 28:16.04.92 - Antidepressants, Misc | 1P | |
| Zykadia® | ceritinib | Novartis | metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive | 03/18/2019 | 10:00 - Antineoplastic Agents | 3S | |
| Kemeya® | drospirenone; ethinyl estradiol | Sun | birth control | 03/13/2019 | 68:12 - Contraceptives | S | |
| Rocklatan® | netarsudil; latanoprost | Aerie | reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension | 03/12/2019 | 52:40.32 - Rho Kinase Inhibitors; 52:40.28 - Prostaglandin Analogs | 4S | |
| Trazimera® | trastuzumab-qyyp | Pfizer | HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma | 03/11/2019 | 10:00 - Antineoplastic Agents | 1 | |
| Spravato® | esketamine | Janssen | treatment-resistant depression (TRD) | 03/05/2019 | 28:16.04.92 - Antidepressants, Miscellaneous | 2P | |
| Herceptin Hylecta® | trastuzumab; hyaluronidase-oysk | Genentech | HER2-overexpressing breast cancer | 02/28/2019 | 10:00 - Antineoplastic Agents | 2P/O | |
| Adhansia XR® | methylphenidate | Purdue | Attention Deficit Hyperactivity Disorder (ADHD) | 02/27/2019 | 28:20.32 - Respiratory and CNS Stimulants | 3S | |
| Lotemax® SM | loteprednol etabonate | Bausch & Lomb | postoperative inflammation and pain following ocular surgery | 02/22/2019 | 52:08.08 - Corticosteroids | 5S | |
| Esperoct® | antihemophilic factor (recombinant), glycopegylated-exei (INN: turoctocog alfa pegol) | Novo Nordisk | hemophilia A | 02/19/2019 | 20:28.16 - Hemostatics | I | |
| Egaten® | triclabendazole | Novartis | fascioliasis (liver fluke infestation) | 02/13/2019 | 8:08 - Anthelmintics | 1S | |
| Sylevia® | ethinyl estradiol; levonorgestrel | Sun | birth control | 02/06/2019 | 68:12 - Contraceptives | I | |
| Cablivi® | caplacizumab-yhdp | Ablynx | acquired thrombotic thrombocytopenic purpura (aTTP) | 02/06/2019 | 20:12.92 - Antithrombotic Agents, Misc | 2a | |
| AlyQ® | tadalafil | Teva | pulmonary arterial hypertension (PAH) | 02/05/2019 | 24:12.12 - Phosphodiesterase Type 5 Inhibitors; 48:48 - Vasodilating Agents | 2( | |
| Jeuveau® | prabotulinumtoxinA-xvfs | Evolus | glabellar lines | 02/01/2019 | 92:92 - Other Miscellaneous Therapeutic Agents | 2P/O | |
| Evekeo ODT® | amphetamine sulfate | Arbor | attention deficit hyperactivity disorder (ADHD) | 01/30/2019 | 28:20.04 - Amphetamines | 3S | |
| Gloperba® | colchicine | Romeg | prophylaxis of gout flares | 01/30/2019 | 92:16 - Antigout Agents | 3S | |
| Wixela Inhub | fluticasone propionate; salmeterol xinafoate | Mylan | asthma; COPD | 01/30/2019 | 68:04 - Adrenals; 12:12.08.12 - Selective beta2-Adrenergic Agonists | T | |
| Tosymra® | sumatriptan | Dr Reddys | migraine headaches | 01/25/2019 | 28:32.28 - Selective Serotonin Agonists | 3S | |
| Ontruzant® | trastuzumab-dttb | Samsung Bioepis | HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma | 01/18/2019 | 10:00 - Antineoplastic Agents | ||
| Ultomiris® | ravulizumab-cwvz | Alexion | paroxysmal nocturnal hemoglobinuria (PNH) | 12/21/2018 | 92:32 - Complement Inhibitors | 1( | |
| Elzonris® | tagraxofusp-erzs | Stemline | blastic plasmacytoid dendritic cell neoplasm (BPDCN) | 12/21/2018 | 10:00 - Antineoplastic Agents | 1P | |
| Inbrija® | levodopa | Acorda | off episodes in Parkinson's disease | 12/21/2018 | 28:36.16 - Dopamine Precursors | 3S | |
| Brixadi® | buprenorphine | Braeburn | moderate to severe pain | 12/21/2018 | 28:08.12 - Opiate Partial Agonists | 3P | |
| Bretylium | bretylium tosylate | ANI Pharmaceuticals | prophylaxis and therapy of ventricular fibrillation and also indicated in the treatment of life-threatening ventricular arrhythmias, except in the case of digitalis induced arrhythmias | 12/21/2018 | 24:04.04.20 - Class III Antiarrhythmics | 1P/O | |
| Vaxelis® | diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine | MCM Vaccines | active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae (H. influenzae) type b | 12/21/2018 | 80:12 - Vaccines | 1n | |
| Elepsia XR® | levetiracetam | Sun | partial-onset seizures | 12/20/2018 | 28:12.92 - Anticonvulsants, Miscellaneous | 5S | |
| Asparlas® | calaspargase pegol-mknl | Servier | acute lymphoblastic leukemia (ALL) | 12/20/2018 | 10:00 - Antineoplastic Agents | 1( | |
| Licart® | diclofenac epolamine | Institut Biochimique | acute pain due to minor strains, sprains, and contusions | 12/19/2018 | 28:08.04.92 - Other Nonsteroidal Anti-inflammatory Agents | 3/4S | |
| Ezallor® | rosuvastatin | Sun | dyslipidemias | 12/18/2018 | 24:06.08 - HMG-CoA Reductase Inhibitors | 5S | |
| Motegrity® | prucalopride | Shire | chronic idiopathic constipation (CIC) | 12/14/2018 | 56:32 - Prokinetic Agents | 1S | |
| Herzuma® | trastuzumab-pkrb | Celltrion | HER2-overexpressing breast cancer | 12/14/2018 | 10:00 - Antineoplastic Agents | 1P/O | |
| Cutaquig® | immune globulin subcutaneous, human-hipp | Octapharma | primary humoral immunodeficiency (PI) | 12/12/2018 | 80:04 - Antitoxins and Immune Globulins | 1 | |
| Tolsura® | itraconazole | Mayne | blastomycosis, histoplasmosis, aspergillosis | 12/11/2018 | 8:14 - Antifungals | 5S | |
| Dvorah® | acetaminophen; caffeine; dihydrocodeine | Larken | moderate to moderately severe pain | 12/06/2018 | 28:08.92 - Analgesics and Antipyretics, Misc; 28:20.32 - Respiratory and CNS Stimulants; 28:08.08 - Opiate Agonists | ||
| Xospata® | gilteritinib | Astellas | relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation | 11/28/2018 | 10:00 - Antineoplastic Agents | 1S | |
| Truxima® | rituximab-abbs | Celltrion | CD20-positive B-cell non-Hodgkin's lymphoma (NHL) | 11/28/2018 | 10:00 - Antineoplastic Agents | 1( | |
| Firdapse® | amifampridine phosphate | Catalyst | Lambert-Eaton myasthenic syndrome (LEMS) in adults | 11/28/2018 | 92:92 - Other Miscellaneous Therapeutic Agents | 1O/P | |
| Vitrakvi® | larotrectinib | Loxo | solid tumors with NTRK gene fusion | 11/26/2018 | 10:00 - Antineoplastic Agents | 1P | |
| Daurismo® | glasdegib | Pfizer | acute myeloid leukemia (AML) | 11/21/2018 | 10:00 - Antineoplastic Agents | 1P | |
| Spy Agent Green® | indocyanine green | Novadaq | visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion; extrahepatic biliary ducts; and lymph nodes and lymphatic vessels | 11/21/2018 | 36:68 - Roentgenographic and Other Imaging Agents | 5S | |
| ReadyPrep CHG® | chlorhexidine gluconate | Medline | topical disinfectant | 11/20/2018 | 84:04.92 - Local Anti-infectives, Misc | 5S | |
| Gamifant® | emapalumab-lzsg | Novimmune | primary hemophagocytic lymphohistiocytosis (HLH) | 11/20/2018 | 92:44 - Immunosuppressive Agents | 1( | |
| Aemcolo® | rifamycin | Cosmo | travelers' diarrhea due to noninvasive E. coli | 11/16/2018 | 8:12.28.30 - Rifamycins | 1P | |
| Temixys® | lamivudine; tenofovir (TDF) | Celltrion | HIV-1 infection | 11/16/2018 | 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors | 5S | |
| Yupelri® | revefenacin | Theravance | maintenance of chronic obstructive pulmonary disease (COPD) | 11/09/2018 | 12:08.08 - Antimuscarinics/Antispasmodics | 1S | |
| Bryhali® (previously Jemdel) | halobetasol propionate | Dow | plaque psoriasis | 11/06/2018 | 84:06.08 - Corticosteroids | 3S | |
| Dsuvia® | sufentanil | AcelRx | acute severe pain | 11/02/2018 | 28:08.08 - Opiate Agonists | 3S | |
| Lorbrena® | lorlatinib | Pfizer | anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) | 11/02/2018 | 10:00 - Antineoplastic Agents | 1P | |
| Udenyca® | pegfilgrastim-cbqv | Coherus | febrile neutropenia | 11/02/2018 | 20:16 - Hematopoietic Agents | 1P/O | |
| Sympazan® | clobazam | Aquestive | seizures associated with Lennox-Gastaut Syndrome (LGS) | 11/01/2018 | 28:12.08 - Benzodiazepines | 3S | |
| Hyrimoz® | adalimumab-adaz | Sandoz | RA, JIA, PsA, AS, CD, UC, Ps | 10/30/2018 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents; 56:92 - GI Drugs, Misc | 1P/O | |
| Bijuva® | estradiol; progesterone | Therapeutics MD | moderate to severe vasomotor symptoms due to menopause | 10/28/2018 | 68:16.04 - Estrogens; 68:32 - Progestins | 4S | |
| Xofluza® | baloxavir | Shionogi | acute uncomplicated influenza virus infection | 10/24/2018 | 8:18.92 - Antivirals, Misc | 1P | |
| Qmiiz® ODT | meloxicam | Tersera | osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA) | 10/19/2018 | 28:08.04.92 - Other Nonsteroidal Anti-inflammatory Agents | 3S | |
| Khapzory® | levoleucovorin | Spectrum | rescue after high-dose MTX therapy; folic acid antagonists overdosage; metastatic colorectal cancer in combo with fluorouracil | 10/19/2018 | 92:12 - Antidotes | 2S | |
| Talzenna® | talazoparib | Pfizer | deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer | 10/16/2018 | 10:00 - Antineoplastic Agents | 1S | |
| Yutiq™ | fluocinolone acetonide | Eyepoint | chronic non-infectious posterior segment uveitis | 10/12/2018 | 52:08.08 - Corticosteroids (EENT) | 5S | |
| Tegsedi® | inotersen | Ionis | polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) | 10/05/2018 | 92:18 - Antisense Oligonucleotides (ASO) | 1P | |
| Revcovi® | elapegademase-lvlr | Leadiant | adenosine deaminase severe combined immune deficiency (ADA-SCID) | 10/05/2018 | 44:00 - Enzymes | 1S | |
| Nuzyra® | omadacycline | Paratek | community-acquired bacterial pneumonia (CABP); acute bacterial skin and skin structure infections (ABSSSI) | 10/02/2018 | 8:12.24.04 - Aminomethylcyclines (new class) | 1P | |
| Seysara® | sarecycline | Allergan | inflammatory lesions of non-nodular moderate to severe acne vulgaris | 10/01/2018 | 8:12.24.04 - Aminomethylcyclines | 1S | |
| Arikayce® | amikacin liposome inhalation | Insmed | refractory Mycobacterium avium complex (MAC) lung disease | 09/28/2018 | 8:12.02 - Aminoglycosides | 3P | |
| Xyosted® | testosterone enanthate | Antares | replacement therapy in males due to deficiency or absence of endogenous testosterone | 09/28/2018 | 68:08 - Androgens | 3S | |
| Libtayo® | cemiplimab-rwlc | Regeneron | metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC | 09/28/2018 | 10:00 - Antineoplastic Agents | 9 | |
| Vizimpro® | dacomitinib | Pfizer | first-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR mutations | 09/27/2018 | 10:00 - Antineoplastic Agents | 1/4P | |
| Emgality® | galcanezumab-gnlm | Eli Lilly | migraine headaches | 09/27/2018 | 28:32.92 - Antimigraine Agents, Misc | C | |
| Copiktra® | duvelisib | Verastem | relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or follicular lymphoma (FL) | 09/24/2018 | 10:00 - Antineoplastic Agents | 1P | |
| Seizalam® | midazolam | Meridian | status epilepticus | 09/14/2018 | 28:12.08 - Benzodiazepines (Anticonvulsants); 28:24.08 - Benzodiazepines (Anxiolytics, Sedatives, and Hypnotics) | 10S | |
| Ajovy® | fremanezumab-vfrm | Teva | migraine headaches | 09/14/2018 | 28:32.92 - Antimigraine Agents, Misc | 9P/O | |
| Lumoxiti® | moxetumomab pasudotox-tdfk | AstraZeneca | relapsed or refractory hairy cell leukemia (HCL) | 09/13/2018 | 10:00 - Antineoplastic Agents | 9( | |
| Xelpros® | latanoprost | Sun | reduction of intraocular pressure in open-angle glaucoma or ocular hypertension | 09/12/2018 | 52:40.28 - Prostaglandin Analogs | 3S | |
| Cassipa® | buprenorphine; naloxone | Teva | opioid dependence | 09/07/2018 | 28:08.12 - Opiate Partial Agonists; 28:10 - Opiate Antagonists | 5S | |
| Tiglutik® | riluzole | Italfarmaco SPA | amyotrophic lateral sclerosis (ALS) | 09/05/2018 | 28:92 - Central Nervous System Agents, Misc | 3S | |
| Sympazan® | clobazam | Aquestive | seizures associated with Lennox-Gastaut Syndrome | 08/31/2018 | 28:12.08 - Benzodiazepines | 3S | |
| Pifeltro® | doravirine | Merck Sharp Dohme | HIV-1 infection | 08/30/2018 | 8:18.08.16 - HIV Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) | 1S | |
| Delstrigo® | doravirine; lamivudine; tenofovir (TDF) | Merck Sharp Dohme | HIV-1 infection | 08/30/2018 | 8:18.08.16 - HIV Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs); 8:18.08.20; 8:18.08.20 | 4S | |
| Jivi® | antihemophilic factor (recombinant), PEGylated-aucl (INN: damoctocog alfa pegol) | Bayer | bleeding management/prophylaxis with hemophilia A (congenital Factor VIII deficiency) | 08/29/2018 | 20:28.16 - Hemostatics | 8e | |
| Xerava® | eravacycline | Tetraphase | complicated intra-abdominal infections except cUTI | 08/27/2018 | 8:12.24.08 - Fluorocyclines (new class) | 1P | |
| Takhzyro® | lanadelumab-flyo | Dyax | hereditary angioedema | 08/23/2018 | 92:32 - Complement Inhibitors | 8P/O | |
| Altreno® | tretinoin | Dow | acne vulgaris | 08/23/2018 | 84:16 - Cell Stimulants and Proliferants | 5 | |
| Inveltys® | loteprednol etabonate | Kala | post-operative inflammation and pain following ocular surgery | 08/22/2018 | 52:08.08 - Corticosteroids | 5S | |
| Oxervate® | cenegermin-bkbg | Dompé | neurotrophic keratitis | 08/22/2018 | 52:92 - EENT Drugs, Misc | 351(a) | |
| Diacomit® | stiripentol | Biocodex SA | seizures assoc with Dravet syndrome together with clobazam | 08/20/2018 | 28:12.92 - Anticonvulsants, Misc | 1P | |
| Cequa® | cyclosporine | Sun Pharma | keratoconjunctivitis sicca (dry eye) | 08/14/2018 | 52:08.92 - Anti-inflammatory Agents, Misc | 5S | |
| Galafold® | migalastat | Amicus | Fabry disease | 08/10/2018 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P | |
| Annovera® | segesterone; ethinyl estradiol | Population Council | combination hormonal contraceptive (CHC) | 08/10/2018 | 68:12 - Contraceptives | 1/4S | |
| Onpattro® | patisiran | Alnylam | polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) | 08/10/2018 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P | |
| Poteligeo® | mogamulizumab-kpkc | Kyowa Kirin | relapsed or refractory mycosis fungoides or Sezary syndrome | 08/08/2018 | 10:00 - Antineoplastic Agents | ||
| Arakoda® | tafenoquine | 60 Degrees | prophylaxis of malaria | 08/08/2018 | 8:30.08 - Antimalarials | 5S | |
| Panzyga® | immune globulin intravenous, human-ifas | Octapharma | primary humoral immunodeficiency (PI); chronic immune thrombocytopenic purpura (ITP) | 08/02/2018 | 80:04 - Antitoxins and Immune Globulins | BUH | |
| Azedra® | iobenguane I-131 | Progenics | pheochromocytoma or paraganglioma | 07/31/2018 | 10:00 - Antineoplastic Agents | 5P | |
| Mulpleta® | lusutrombopag | Shionogi | thrombocytopenia in adults with chronic liver disease | 07/31/2018 | 20:16 - Hematopoietic Agents | 1P | |
| Omegaven® | fish oil triglycerides | Fresenius Kabi | source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC) | 07/27/2018 | 40:20 - Caloric Agents | 1P | |
| Orilissa® | elagolix | Abbvie | management of pain associated with endometriosis | 07/23/2018 | 68:18.04 - Antigonadotropins | 1P | |
| Krintafel® | tafenoquine | GlaxoSmithKline | radical cure (prevention of relapse) of Plasmodium vivax malaria | 07/20/2018 | 8:30.08 - Antimalarials | 1P | |
| Tibsovo® | ivosidenib | Agios | relapsed or refractory acute myeloid leukemia (AML) | 07/20/2018 | 10:00 - Antineoplastic Agents | 1P | |
| Nivestym® | filgrastim-aafi | Hospira | febrile neutropenia | 07/20/2018 | 20:16 - Hematopoietic Agents | 7P/O | |
| Symtuza® | darunavir; cobicistat; emtracitabine; tenofovir alafenamide | Janssen | HIV-1 infection | 07/17/2018 | 8:18.08.08; 92:92; 8:18.08.20; 8:18.08.20 | 4S | |
| TPOXX® | tecovirimat | Siga | smallpox disease caused by variola virus | 07/13/2018 | 8:18.92 - Antivirals, Misc | 1P | |
| Iclevia® | ethinyl estradiol; levonorgestrel | Aurobindo | birth control | 06/29/2018 | 68:12 - Contraceptives | I | |
| Qbrexza® | glycopyrronium tosylate | Dermira | primary axillary hyperhidrosis | 06/28/2018 | 84:92 - Skin and Mucous Membrane Agents, Misc; 12:08.08 - Antimuscarinics/Antispasmodics | 3S | |
| Braftovi® | encorafenib | Array Biopharma | unresectable or metastatic melanoma with a BRAF V600E or V600K mutation; in combination with binimetinib | 06/27/2018 | 10:00 - Antineoplastic Agents | 1/4S | |
| Mektovi® | binimetinib | Array Biopharma | unresectable or metastatic melanoma with a BRAF V600E or V600K mutation; in combination with encorafenib | 06/27/2018 | 10:00 - Antineoplastic Agents | 1/4S | |
| Zemdri® | plazomicin | Achaogen | complicated urinary tract infections (cUTI) including pyelonephritis | 06/25/2018 | 8:12.02 - Aminoglycosides | 1P | |
| Epidiolex® | cannabidiol | GW Research | seizures associated with Lennox-Gastaut or Dravet syndrome | 06/25/2018 | 28:12.92 - Anticonvulsants, Misc | 1P | |
| Nocdurna® | desmopressin | Ferring | nocturia due to nocturnal polyuria | 06/21/2018 | 68:28 - Pituitary | 5S | |
| Ablysinol® | dehydrated alcohol | Belcher | alcohol septal ablation | 06/21/2018 | 24:16 - Sclerosing Agents | 5S | |
| Cinryze® | C1 esterase inhibitor (human) | Lev | prophylaxis of hereditary angioedema (HAE) | 06/20/2018 | 92:32 - Complement Inhibitors | 6( | |
| Lymepak® | doxycycline hyclate | Chartwell | early Lyme disease | 06/15/2018 | 8:12.24 - Tetracyclines | 5S | |
| moxidectin | moxidectin | Medicines Development | onchocerciasis | 06/13/2018 | 8:08 - Anthelmintics | 1P/O | |
| Fulphila® | pegfilgrastim-jmdb | Mylan | febrile neutropenia | 06/04/2018 | 20:16 - Hematopoietic Agents | 6P/O | |
| Olumiant® | baricitinib | Eli Lilly | moderate to severe rheumatoid arthritis | 05/31/2018 | 92:36 - Disease-modifying Antirheumatic Drugs (DMARD) | 1S | |
| Consensi® | amlodipine; celecoxib | Kitov | combination therapy for hypertension and osteoarthritis | 05/31/2018 | 24:28.08 - Dihydropyridines; 28:08.04.08 - Cyclooxygenase-2 (COX-2) Inhibitors | 4S | |
| Imvexxy® | estradiol | Therapeutics MD | moderate to severe dyspareunia due to menopause | 05/29/2018 | 68:16.04 - Estrogens | 5S | |
| Palynziq® | pegvaliase-pqpz | Biomarin | hyperphenylalaninaemia in patients with phenylketonuria (PKU) | 05/24/2018 | 44:00 - Enzymes | 5( | |
| Yonsa® | abiraterone | Sun Pharma | metastatic castration-resistant prostate cancer (CRPC) | 05/22/2018 | 10:00 - Antineoplastic Agents | 5S | |
| Doptelet® | avatrombopag | Akarx | thrombocytopenia | 05/21/2018 | 20:16 - Hematopoietic Agents | 1P | |
| Lokelma® | sodium zirconium cyclosilicate | AstraZeneca | hyperkalemia | 05/18/2018 | 40:18.18 - Potassium-removing Agents | 1S | |
| Aimovig® | erenumab-aooe | Amgen | migraine headaches | 05/17/2018 | 28:32.92 - Antimigraine Agents, Misc | 5P/O | |
| Lucemyra® | lofexidine | US Worldmeds | mitigation of opioid withdrawal symptoms | 05/16/2018 | 12:12.04 - alpha-Adrenergic Agonists | 1P | |
| Retacrit® | epoetin alfa-epbx | Hospira | anemia | 05/15/2018 | 20:16 - Hematopoietic Agents | 5P/O | |
| Plenvu® | PEG 3350; sod ascorbate; sod sulfate; ascorbic acid; sod chloride; pot chloride | Northstar | colon preparation for colonoscopy | 05/04/2018 | 56:12 - Cathartics and Laxatives | 2S | |
| Andexxa® | factor Xa (recombinant), inactivated-zhzo | Portola | reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding | 05/03/2018 | 20:28.92 - Antihemorrhagic Agents, Misc | B L | |
| Jynarque® | tolvaptan | Otsuka | autosomal dominant polycystic kidney disease (ADPKD) | 04/23/2018 | 40:28.28 - Vasopressin Antagonists | 10P | |
| Akynzeo® for Injection | fosnetupitant; palonosetron | Helsinn | acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy | 04/19/2018 | 56:22.32 - Neurokinin-1 Receptor Antagonists; 56:22.20 - 5-HT3 Receptor Antagonists | 1S | |
| Tavalisse® | fostamatinib | Rigel | chronic immune thrombocytopenia (ITP) | 04/17/2018 | 20:92 - Blood Formation, Coagulation, and Thrombosis Agents; Misc | 1S | |
| Crysvita® | burosumab-twza | Ultragenyx | X-linked hypophosphatemia (a vitamin D-resistant form of rickets) | 04/17/2018 | 40:92 - Electrolytic, Caloric, and Water Balance Agents; Misc | 4k | |
| Zumandimine® | drospirenone; ethinyl estradiol | Aurobindo | birth control | 03/26/2018 | 68:12 - Contraceptives | S | |
| Symfi® | efavirenz; lamivudine; tenofovir disoproxil | Matrix | HIV-1 infection | 03/22/2018 | 8:18.08.16 - HIV Nonnucleoside Reverse Transcriptase Inhibitors; 8:18.08.20 HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors | 4 | |
| Ilumya® | tildrakizumab-asmn | MSD / Sun Pharma | plaque psoriasis | 03/20/2018 | 84:92 - Skin and Mucous Membrane Agents, Misc | D | |
| Trogarzo® | ibalizumab-uiyk | Taimed | HIV-1 infection with multidrug resistance | 03/06/2018 | 8:18.08.04 - HIV Entry and Fusion Inhibitors | 3P/O | |
| Mytesi® (previously Fulyzaq®) | crofelemer | Napo | noninfectious diarrhea caused by antiretroviral therapy | 03/06/2018 | 56:08 - Antidiarrhea Agents | 3P/O | |
| Cimduo® | lamivudine; tenofovir disoproxil fumerate | Matrix | HIV-1 infection | 02/28/2018 | 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NNRTI) | 4P | |
| ZTLido® | lidocaine | Scilex | pain associated with post-herpetic neuralgia (PHN) | 02/28/2018 | 72:00 - Local Anesthetics | 5S | |
| Apadaz® | benzhydrocodone; acetaminophen | KemPharm | acute severe pain | 02/23/2018 | 28:08.08 - Opiate Agonists; 28:08.92 - Analgesics and Antipyretics, Misc | 4S | |
| Osmolex ER® | amantadine | Osmotica Pharm | Parkinsons; drug-induced extrapyramidal reactions | 02/16/2018 | 28:36.04 - Adamantanes | 3S | |
| Erleada® | apalutamide | Janssen | non-metastatic castration-resistant prostate cancer | 02/14/2018 | 10:00 - Antineoplastic Agents | 1P | |
| Symdeko® | tezacaftor; ivacaftor | Vertex | cystic fibrosis (CF) with mutation of CFTR gene | 02/12/2018 | 48:14.04 - Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Correctors; 48:14.12 - Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiators | 1P | |
| Biktarvy® | bictegravir; emtracitabine; tenofovir alafenamide | Gilead | HIV-1 infection | 02/07/2018 | 8:18.08.12 - HIV Integrase Inhibitors; 8:18.08.20 HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors | 1/4P | |
| Symfi Lo® | efavirenz; lamivudine; tenofovir disoproxil | Mylan | HIV-1 infection | 02/05/2018 | 8:18.08.16 - HIV Nonnucleoside Reverse Transcriptase Inhibitors; 8:18.08.20 HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors | 3P | |
| Lutathera® | lutetium Lu-177 dotatate | Advanced Accelerator Applications | somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) | 01/26/2018 | 10:00 - Antineoplastic Agents; 78:00 - Radioactive Agents | 1P | |
| Firvanq® | vancomoycin | RxM Therapeutics | C. diff-associated diarrhea, enterocolitis (S. aureus [incl MRSA]) | 01/26/2018 | 8:12.28.16 - Glycopeptides | 5P | |
| Lumify® (OTC) | brimonidine | Bausch and Lomb | redness due to minor eye irritations | 12/22/2017 | 52:40.04 - alpha-Adrenergic Agonists | 5/8S | |
| Siklos® | hydroxyurea | Addmedica | sickle cell anemia with recurrent moderate to severe painful crises in pediatric patients | 12/21/2017 | 10:00 - Antineoplastic Agents | 3P | |
| Giapreza® | angiotensin II | La Jolla | increase blood pressure in septic shock | 12/21/2017 | 68:44 - Renin-Angiotensin-Aldosterone System (RAAS) (new class) | 1P | |
| Macrilen® | macimorelin | Aeterna Zentaris | diagnosis of adult growth hormone deficiency | 12/20/2017 | 36:66 - Pituitary | 1S | |
| Prexxartan® | valsartan | Carmel | hypertension, heart failure, stable left ventricular failure or left ventricular dysfunction following myocardial infarction | 12/19/2017 | 24:32.08 - Angiotensin II Receptor Antagonists | 3S | |
| Steglatro® | ertugliflozin | Merck Sharp Dohme | type 2 diabetes mellitus | 12/19/2017 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors | 1S | |
| Steglujan® | ertugliflozin; sitagliptin | Merck Sharp Dohme | type 2 diabetes mellitus | 12/19/2017 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.05 - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors | 1/4S | |
| Stegluromet® | ertugliflozin; metformin | Merck Sharp Dohme | type 2 diabetes mellitus | 12/19/2017 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.04 - Biguanides | 1/4S | |
| Luxturna® | voretigene neparvovec-rzyl | Spark Therapeutics | biallelic RPE65 mutation-associated retinal dystrophy | 12/19/2017 | 26:12 - Gene Therapy | ||
| Rhopressa® | netarsudil | Aerie | open-angle glaucoma or ocular hypertension | 12/18/2017 | 52:40.92 - Antiglaucoma Agents, Miscellaneous | 1S | |
| Altafluor Benox® | fluorescein sodium; benoxinate hydrochloride | Altaire | tonometry, gonioscopy | 12/14/2017 | 36:58 - Ocular Disorders; 52:16 - Local Anesthetics | 4P | |
| Eskata® | hydrogen peroxide | Aclaris | seborrheic keratoses | 12/14/2017 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous (was 84:28) | 5S | |
| Goprelto® | cocaine | Genus | local anesthesia of the nasal cavities | 12/14/2017 | 52:16 - Local Anesthetics | 5S | |
| Ixifi® | infliximab-qbtx | Pfizer | Crohn's disease; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; plaque psoriasis | 12/13/2017 | 92:20 - Immunomodulatory Agents; 92:36 - Disease-modifying Antirheumatic Drugs | 1P/O | |
| Tydemy® | drospirenone; ethinyl estradiol; levomefolate calcium | Lupin | birth control | 12/12/2017 | 68:12 - Contraceptives | 2S | |
| Xepi® | ozenoxacin | Ferrer | topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes | 12/11/2017 | 84:04.04 - Antibacterials | 1S | |
| Admelog® | insulin lispro | Sanofi Aventis | diabetes mellitus | 12/11/2017 | 68:20.08 - Insulins | 5S | |
| Sinuva® Sinus Implant | mometasone furoate | Intersect ENT | nasal polyps | 12/08/2017 | 52:08.08 - Corticosteroids | 3S | |
| Lonhala Magnair® | glycopyrrolate | Sunovion | long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) | 12/05/2017 | 12:08.08 - Antimuscarinics/Antispasmodics | 3/4S | |
| Ozempic® | semaglutide | Novo Nordisk | type 2 diabetes mellitus | 12/05/2017 | 68:20.06 - Incretin Mimetics | 1S | |
| Ogivri® | trastuzumab-dkst | Mylan | HER2-overexpressing breast cancer and metastatic gastric/gastroesophageal junction adenocarcinoma | 12/01/2017 | 10:00 - Antineoplastic Agents | ||
| Sublocade® | buprenorphine | Indivior | moderate to severe opioid use disorder | 11/30/2017 | 28:08.12 - Opiate Partial Agonists | 3P | |
| Impoyz® | clobetasol propionate | Promius | moderate-to-severe plaque psoriasis | 11/28/2017 | 84:06.08 - Corticosteroids | 5S | |
| Clenpiq® | sodium picosulfate; magnesium oxide; anhydrous citrix acid | Ferring | colon preparation for colonoscopy | 11/28/2017 | 56:12 - Cathartics and Laxatives | 3S | |
| Juluca® | dolutegravir; rilpivirine | Viiv | HIV-1 infection | 11/21/2017 | 8:18.08.12 - HIV Integrase Inhibitors; 8:18.08.16 - HIV Nonnucleoside Reverse Transcriptase Inhibitors | 4P | |
| Hemlibra® | emicizumab-kxwh | Genentech | hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors | 11/16/2017 | 20:28.16 - Hemostatics | 351(a) | |
| Mepsevii® | vestronidase alfa-vjbk | UltraGenyx | mucopolysaccharidosis type VII (MPS VII, Sly syndrome) | 11/15/2017 | 44:00 - Enzymes | 1r | |
| Fasenra® | benralizumab | AstraZeneca | add-on maintenance of severe asthma | 11/14/2017 | 48:10.20 - Interleukin Antagonists | ||
| Abilify Mycite® | aripiprazole with ingestible event marker (IEM) | Otsuka | schizophrenia, bipolar disorder, major depressive disorder | 11/13/2017 | 28:16.08.04 - Atypical Antipsychotics | 4 | |
| Heplisav-B® | hepatitis B vaccine, recombinant | Dynavax | prevention of hepatitis B (HBV) infection | 11/09/2017 | 80:12 - Vaccines | 1c | |
| Cinvanti® | aprepitant | Heron | nausea and vomiting associated with chemotherapy | 11/09/2017 | 56:22.32 - Neurokinin-1 (NK1) Receptor Antagonists | 3 | |
| Prevymis® | letermovir | MSD | prophylaxis of cytomegalovirus (CMV) infection | 11/08/2017 | 8:18.92 - Antivirals, Misc | 1 | |
| Vyzulta® | latanoprostene bunod | Valeant | open-angle glaucoma or ocular hypertension | 11/02/2017 | 52:40.28 - Prostaglandin Analogs | 1 | |
| Calquence® | acalabrutinib | Acerta | mantle cell lymphoma (MCL) | 10/31/2017 | 10:00 - Antineoplastic Agents | 1P | |
| Shingrix® | zoster vaccine recombinant | GSK | shingles (herpes zoster) vaccine | 10/20/2017 | 80:12 - Vaccines | 1c | |
| Yescarta® | axicabtagene ciloleucel | Kite | certain types of non-Hodgkin lymphoma (NHL) | 10/18/2017 | 26:12 - Gene Therapy; 10:00 - Antineoplastic Agents | 1( | |
| Lyrica CR® | pregabalin | Pfizer | neuropathic pain associated with diabetic peripheral neuropathy (DPN); postherpetic neuralgia (PHN) | 10/11/2017 | 28:12.92 - Anticonvulsants, Misc; 28:40 - Fibromyalgia Agents; 28:08.92 - Analgesics and Antipyretics, Misc | 5S | |
| Zilretta® | triamcinolone acetonide | Flexion | osteoarthritis knee pain | 10/06/2017 | 68:04 - Adrenals | 5S | |
| Ascor® | ascorbic acid | McGuff | scurvy | 10/02/2017 | 88:12 - Vitamin C | 7S | |
| Fiasp® | insulin aspart | Novo Nordisk | diabetes | 09/29/2017 | 68:20.08 - Insulins | 5S | |
| Verzenio® | abemaciclib | Eli Lilly | HR+,HER2- advanced or metastatic breast cancer | 09/28/2017 | 10:00 - Antineoplastic Agents | 1S | |
| Clorotekal® | chloroprocaine | Sintetica | spinal anesthesia | 09/26/2017 | 72:00 - Local Anesthetics | 5S | |
| Xhance® | fluticasone propionate | Optnose | rhinitis | 09/18/2017 | 52:08.08 - Corticosteroids | 5S | |
| Trelegy Ellipta® | fluticasone furoate; umeclidinium; vilanterol | GlaxoSmithKline | chronic obstructive pulmonary disease (COPD) | 09/18/2017 | 68:04 - Adrenals; 12:08.08 - Antimuscarinics/Antispasmodics; 12:12.08.12 - Selective beta-2-Adrenergic Agonists | 5S | |
| Adzenys® ER | amphetamine | Neos | attention deficit hyperactivity disorder (ADHD) | 09/15/2017 | 28:20.04 - Amphetamines | 3S | |
| Solosec® | secnidazole | Symbiomix | bacterial vaginosis | 09/15/2017 | 8:30.92 - Antiprotozoals, Misc | 1P | |
| Aliqopa® | copanlisib | Bayer | relapsed follicular lymphoma (FL) | 09/14/2017 | 10:00 - Antineoplastic Agents | 1P/O | |
| Mvasi® | bevacizumb-awwb | Amgen | metastatic colorectal cancer; non-squamous non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer | 09/14/2017 | 10:00 - Antineoplastic Agents | 9P/O | |
| Mylotarg® | gemtuzumab | Wyeth | acute myeloid leukemia (CD33+ AML) | 09/01/2017 | 10:00 - Antineoplastic Agents | 9 | |
| Kymriah® | tisagenlecleucel | Novartis | B-cell precursor acute lymphoblastic leukemia (ALL) | 08/30/2017 | 26:12 - Gene Therapy (new class); 10:00 - Antineoplastic Agents | 8( | |
| benznidazole | benznidazole | Chemo Research | Chagas disease (American trypanosomiasis) | 08/29/2017 | 8:30.92 - Antiprotozoals, Misc | 1P/O | |
| Vabomere® | meropenem; vaborbactam | Rempex | complicated urinary tract infections (cUTI) | 08/29/2017 | 8:12.07.08 - Carbapenems | 1/4P | |
| Cyltezo® | adalimumab-adbm | Boehringer Ingelheim | rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulerative colitis (UC), plaque psoriasis (Ps) | 08/25/2017 | 92:36 - Disease-modifying Antirheumatic Drugs, 92:20 - Immunomodulatory Agents, 56:92 - GI Drugs, Misc | ||
| Gocovri® | amantadine | Adamas | dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy | 08/24/2017 | 28:36.04 - Adamantanes | 3S/O | |
| Kedrab® | rabies immune globulin (human) | Kamada | post-exposure prophylaxis of rabies infection | 08/23/2017 | 80:04 - Antitoxins and Immune Globulins | BUA | |
| Duzallo® | lesinurad; allopurinol | Ardea | hyperuricemia associated with gout | 08/18/2017 | 40:40 - Uricosuric Agents; 92:16 - Antigout Agents | 4S | |
| Lynparza® | olaparib | AstraZeneca | ovarian cancer | 08/17/2017 | 10:00 - Antineoplastic Agents | 3P | |
| Drax Exametazime | drax exametazime | Jubilant | leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intraabdominal infection and inflammatory bowel disease | 08/17/2017 | 36:68 - Roentgenography | 5S | |
| Besponsa® | inotuzumab | Wyeth | relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) | 08/17/2017 | 10:00 - Antineoplastic Agents | 1P/O | |
| Carospir® | spironolactone | CMP | heart failure, hypertension, edema | 08/04/2017 | 24:32.20 - Mineralocorticoid (Aldosterone) Receptor Antagonists | 3S | |
| Nikita® | pitavastatin | Lupin | dyslipidemias | 08/04/2017 | 24:06.08 - HMG-CoA Reductase Inhibitors | 2S | |
| Vyxeos® | daunorubicin liposomal; cytarabine | Celator | therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) | 08/03/2017 | 10:00 - Antineoplastic Agents | 4S | |
| Mavyret® | glecaprevir; pibrentasvir | Abbvie | hepatitis C virus (HCV) infection | 08/03/2017 | 8:18.40.20 - HCV Protease Inhibitors; 8:18.40.24 - HCV Replication Complex Inhibitors | 1,4P | |
| Idhifa® | enasidenib | Celgene | acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation | 08/01/2017 | 10:00 - Antineoplastic Agents | 1P | |
| Nityr® | nitisinone | Cycle Pharms | hereditary tyrosinemia type 1 (HT-1) | 07/26/2017 | 92:92 - Other Miscellaneous Therapeutic Agents | 5S | |
| Benlysta® | belimumab | Glaxo Smith Kline | active, autoantibody-positive, systemic lupus erythematosus | 07/20/2017 | 92:44 - Immunosuppressive Agents | ||
| Vosevi® | sofosbuvir; velpatasvir; voxilaprevir | Gilead | hepatitis C virus (HCV) infection | 07/18/2017 | 8:18.40.16 - HCV Polymerase Inhibitors | 1/4P | |
| Nerlynx® | neratinib | Puma | early stage HER2-overexpressed/amplified breast cancer | 07/17/2017 | 10:00 - Antineoplastic Agents | 1S | |
| Zypitamag® | pitavastatin magnesium | Zydus | primary hyperlipidemia or mixed dyslipidemia | 07/14/2017 | 24:06.08 - HMG-CoA Reductase Inhibitors | 2S | |
| Tremfya® | guselkumab | Janssen | moderate-to-severe plaque psoriasis | 07/13/2017 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 7P/O | |
| Endari® | L-glutamine | Emmaus | reduce acute complications associated with sickle cell disease | 07/07/2017 | 92:92 - Other Miscellaneous Therapeutic Agents | 5S | |
| Triptodur® Kit | triptorelin | Arbor | central precocious puberty | 06/29/2017 | 68:18 - Gonadotropins | 5S/O | |
| Bevyxxa® | betrixaban | Portola | prophylaxis of venous thromboembolism (VTE) | 06/23/2017 | 20:12.04.14 - Direct Factor Xa Inhibitors | 1S | |
| Haegarda® | C1 esterase inhibitor (human) | CSL Behring | prophylaxis of hereditary angioedema (HAE) | 06/22/2017 | 92:32 - Complement Inhibitors | 6( | |
| Rituxan Hycela® | rituximab; hyaluronidase (human recombinant) | Genentech | follicular lumphoma (FL); diffuse large B-cell lymphoma (DLBCL); chronic lymphocytic leukemia (CLL) | 06/22/2017 | 10:00 - Antineoplastic Agents | BLT | |
| Mydayis® | amphetamine; dextroamphetamine | Shire | attention deficit hyperactivity disorder (ADHD) | 06/20/2017 | 28:20.04 - Amphetamines | 3S | |
| Baxdela® | delafloxacin | Melinta | acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria | 06/19/2017 | 8:12.18 - Quinolones | 1S | |
| Cotempla XR ODT® | methylphenidate | Neos | attention deficit hyperactivity disorder (ADHD) | 06/19/2017 | 28:20.32 - Respiratory and CNS Stimulants | 3S | |
| Symjepi® | epinephrine | Adamis Pharms | type I allergic reactions, including anaphylaxis | 06/15/2017 | 12:12.12 - a- and ß-Adrenergic Agonists | 5S | |
| Fibryna® | fibrinogen (human) | Octapharma | afibrinogenemia and hypofibrinogenemia | 06/07/2017 | 20:28.16 - Hemostatics | 6P/O | |
| Gleolan® | aminolevulinic acid oral solution | NX | optical imaging | 06/06/2017 | 36:68 - Roentgenographic and Other Imaging Agents | 3P | |
| Rebinyn® | factor IX (recombinant), glycoPEGylated (INN: nonacog beta pegol) | Novo Nordisk | hemophilia B for on-demand treatment and control of bleeding episodes and for perioperative management of bleeding | 05/31/2017 | 20:28.16 - Hemostatics | B-N | |
| Zerviate® | cetirizine hydrochloride | Nicox | ocular itching associated with allergic conjunctivitis | 05/30/2017 | 52:02 - Antiallergic Agents | 3P | |
| Kevzara® | sarilumab | Sanofi | adult rheumatoid arthritis | 05/23/2017 | 92:36 - Disease-modifying Antirheumatic Drugs | 5P/O | |
| Minolira® | minocycline hydrochloride | Dr Reddy's | moderate to severe acne vulgaris | 05/08/2017 | 84:92 - Skin and Mucous Membrane Agents, Misc | 5S | |
| Jadenu® | deferasirox | Novartis | chronic iron overload | 05/08/2017 | 64:00 - Heavy Metal Antagonists | 5S | |
| Radicava® | edaravone | MT Pharma | amyotrophic lateral sclerosis (ALS) | 05/05/2017 | 28:92 - Central Nervous System Agents, Miscellaneous | 1 | |
| Kisqali® Femara® Co-Pack | letrozole; ribociclib | Novartis | hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer | 05/04/2017 | 10:00 - Antineoplastic Agents | 4S | |
| Imfinzi® | durvalumab | AstraZeneca | locally advanced or metastatic urothelial carcinoma | 05/01/2017 | 10:00 - Antineoplastic Agents | ||
| Steritalc® | talc | Novatech | decrease the recurrence of malignant pleural effusions and pneumothorax | 05/01/2017 | 24:16 - Sclerosing Agents | 5S | |
| Rydapt® | midostaurin | Novartis | acute myeloid leukemia (AML) that is FLT3 mutation-positive; aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia | 04/28/2017 | 10:00 - Antineoplastic Agents | 1P | |
| Tymlos® | abaloparatide | Radius | postmenopausal women with osteoporosis at high risk for fracture | 04/28/2017 | 68:24 - Parathyroid | 1/4S | |
| Alunbrig® | brigatinib | Ariad | anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) | 04/28/2017 | 10:00 - Antineoplastic Agents | 1P | |
| Brineura® | cerliponase alfa | Biomarin | indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency. | 04/27/2017 | 44:00 - Enzymes | 4P/O | |
| Xatmep® | methotrexate | Silvergate | acute lymphoblastic leukemia (ALL) in pediatric patients; active polyarticular juvenile idiopathic arthritis (pJIA) | 04/25/2017 | 10:00 - Antineoplastic Agents | 3S | |
| Renflexis® | infliximab-abda | Samsung Bioepsis | Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis | 04/21/2017 | 92:36 - Disease-modifying Antirheumatic Drugs | ||
| Roxybond® | oxycodone | Inspirion | pain | 04/20/2017 | 28:08.08 - Opiate Agonists | 5P | |
| Ingrezza® | valbenazine | Neurocrine Biosciences | tardive dyskinesia | 04/11/2017 | 28:92 - Central Nervous System Agents, Misc | 1P | |
| Austedo® | deutetrabenazine | Teva | Huntington's chorea, tardive dyskinesia | 04/03/2017 | 28:92 - Central Nervous System Agents, Misc | 1S | |
| Dupixent® | dupilumab | Regeneron | moderate-to-severe eczema (atopic dermatitis) | 03/28/2017 | 84:92 - Skin and Mucous Membrane Agents, Misc | 3i | |
| Ocrevus® | ocrelizumab | Genentech | relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) | 03/28/2017 | 92:20 - Immunomodulatory Agents | 3P/O | |
| Zejula® | niraparib | Tesaro | epithelial ovarian, fallopian tube, or primary peritoneal cancer | 03/27/2017 | 10:00 - Antineoplastic Agents | 1P | |
| Symproic® | naldemedine | Shionogi | opioid-induced constipation (OIC) | 03/23/2017 | 56:92 - GI Drugs, Miscellaneous | 1S | |
| Bavencio® | avelumab | EMD Serono | metastatic Merkel cell carcinoma (MCC) | 03/23/2017 | 10:00 - Antineoplastic Agents | 3( | |
| Xadago® | safinamide | Newron | Parkinson's disease | 03/21/2017 | 28:36.32 - Monoamine Oxidase B Inhibitors | 1S | |
| Kisqali® | ribociclib | Novartis | HR+/HER2- advanced or metastatic breast cancer | 03/13/2017 | 10:00 - Antineoplastic Agents | 1P | |
| Noctiva® | desmopressin acetate | Serenity | nocturnal polyuria | 03/03/2017 | 68:28 - Pituitary | 5S | |
| Odactra® | house dust mites (HDM) allergen extract | MSD | HDM-induced allergic rhinitis | 03/01/2017 | 80:02 - Allergenic Extracts | ||
| Xermelo® | telotristat ethyl | Lexicon Pharma | carcinoid syndrom diarrhea | 02/28/2017 | 56:08 - Antidiarrhea Agents | 1S | |
| Qtern® | dapagliflozin; saxagliptin | AstraZeneca | type 2 diabetes mellitus | 02/27/2017 | 68:20.18 - SGLT-2 Inhibitors; 68:20.05 - DPP-4 Inhibitors | 4S | |
| Siliq® | brodalumab | Valeant | plaque psoriasis | 02/15/2017 | 84:92 - Skin and Mucous Membrane Agents, Misc | 2P/O | |
| Emflaza® | deflazacort | Marathon | Duchenne muscular dystrophy (DMD) | 02/09/2017 | 68:04 - Adrenals | 1P | |
| Parsabiv® | etelcalcetide | Kai | secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis | 02/07/2017 | 92:92 - Other Miscellaneous Therapeutic Agents | 1S | |
| ArmonAirTM Respiclick® | fluticasone propionate | Teva | asthma | 01/27/2017 | 68:04 - Adrenals | 5S | |
| AirDuoTM Respiclick® | fluticasone propionate; salmeterol | Teva | asthma | 01/27/2017 | 68:04 - Adrenals; 12:12.08.12 - Selective beta-2-Adrenergic Agonists | 4S | |
| Corphedra® | ephedrine | Par | anesthesia-induced hypotension | 01/27/2017 | 12:12.12 - alpha- and beta-Adrenergic Agonists | 5S | |
| Tepadina® | thiotepa | Adienne SA | reduce risk of graft rejection; adenocarcinoma of the breast or ovary; superficial papillary carcinoma of the urinary bladder; controlling intracavitary effusions | 01/26/2017 | 10:00 - Antineoplastic Agents | 5S | |
| Trulance® | plecanatide | Synergy | chronic idiopathic constipation (CIC) | 01/19/2017 | 56:92 - GI Drugs, Miscellaneous | 1S | |
| Rhofade® | oxymetazoline | Allergan | persistent facial erythema associated with rosacea | 01/18/2017 | 84:92 - Skin and Mucous Membrane Agents, Misc | 10S | |
| Vantrela ER® | hydrocodone | Teva | pain | 01/17/2017 | 28:08.08 - Opiate Agonists | 3S | |
| Esbriet® | pirfenidone | Genentech | idiopathic pulmonary fibrosis (IPF) | 01/11/2017 | 48:02 - Antifibrotic Agents | 3S | |
| Arymo ER® | morphine sulfate | Egalet | severe pain requiring daily, around-the-clock, long-term opioid treatment | 01/09/2017 | 28:08.08 - Opiate Agonists | 5S | |
| Nitrous Oxide | nitrous oxide | Matheson Tri-Gas | general anesthesia; analgesia | 01/09/2017 | 28:04.16 - Inhalation Anesthetics | ||
| Spinraza® | nusinersen | Biogen | spinal muscular atrophy (SMA) | 12/23/2016 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P | |
| Rubraca® | rucaparib | Clovis | BRCA mutation associated advanced ovarian cancer | 12/19/2016 | 10:00 - Antineoplastic Agents | 1P | |
| Tirosint-Sol® | levothyroxine sodium | IBSA | replacement therapy in congenital or acquired hypothyroidism; adjunct to surgery and radiation in management of thyrotropin-dependent well-differentiated thyroid cancer | 12/15/2016 | 68:36.04 - Thyroid Agents | 3S | |
| Eucrisa® | crisaborole | Anacor | topical treatment of mild to moderate atopic dermatitis | 12/14/2016 | 84:06 - Anti-inflammatory Agents | 1S | |
| Synjardy XR® | empagliflozin; metformin | Boehringer Ingelheim | type 2 diabetes mellitus | 12/09/2016 | 68:20.18 - SGLT2 Inhibitors; 68:20.04 - Biguanides | 3S | |
| Xultophy 100/3.6® | insulin degludec; liraglutide | Novo Nordisk | type 2 diabetes mellitus | 11/21/2016 | 68:20.08 - Insulins; 68:20.06 - Incretin Mimetics | 4S | |
| Soliqua 100/33® | insulin glargine; lixisenatide | Sanofi Aventis | type 2 diabetes mellitus | 11/21/2016 | 68:20.08 - Insulins; 68:20.06 - Incretin Mimetics | 4S | |
| Intrarosa® | prasterone | Gilead | moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause | 11/16/2016 | 68:04 - Adrenals | 2/4 | |
| Vemlidy® | tenofovir alafenamide | Gilead | chronic hepatitis B virus infection (HBV) | 11/10/2016 | 8:18.32 - Nucleosides and Nucleotides | 5S | |
| Bonjesta® | doxylamine; pyridoxine | Duchesnay | nausea/vomiting due to pregnancy | 11/07/2016 | 56:22.08 - Antihistamines | 5S | |
| Selzentry® Oral Solution | maraviroc | Viiv | HIV infection | 11/04/2016 | 8:18.08.04 - HIV Entry and Fusion Inhibitors | 3P | |
| Zinplava® | bezlotoxumab | MSD | in combination with antibacterial therapy to treat Clostridium difficile | 10/21/2016 | 80:04 - Antitoxins and Immune Globulins | ||
| Lartruvo® | olaratumab | Eli Lilly | soft tissue sarcoma (STS) | 10/19/2016 | 10:00 - Antineoplastic Agents | 1( | |
| Tecentriq® | atezolizumab | Genentech | metastatic urothelial carcinoma; metastatic NSCLC | 10/18/2016 | 10:00 - Antineoplastic Agents | 1P/O | |
| CarnexIV® | carbamazepine | Lundbeck | seizures | 10/07/2016 | 28:12.92 - Anticonvulsants, Miscellaneous | 3 | |
| Amjevita® | adalimumab-atto | Amgen | rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn's disease (CD), ulverative colitis (UC), plaque psoriasis (Ps) | 09/23/2016 | 92:36 - Disease-modifying Antirheumatic Drugs | 9P/O | |
| Invokamet XR® | canagliflozin; metformin | Janssen | type 2 diabetes mellitus | 09/20/2016 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.04 - Biguanides | 4S | |
| Epaned® | enalapril | Silvergate | hypertension, heart failure, left ventricular dysfunction | 09/20/2016 | 24:32.04 - Angiotensin-Converting Enzyme Inhibitors | 5S | |
| Exondys 51® | eteplirsen | Sarepta | Duchenne muscular dystrophy (DMD) with confirmed mutation of DMD gene that is amenable to exon 51 skipping | 09/19/2016 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P | |
| Kyleena® | levonorgestrel | Bayer | long-acting reversible contraceptive (LARC) (5 years) | 09/16/2016 | 68:12 - Contraceptives | 5 | |
| Yosprala® | aspirin; omeprazole | Aralez | secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers | 09/14/2016 | 20:12.18 - Platelet-aggregation Inhibitors; 56:28.36 - Proton-pump Inhibitors | 9P/O | |
| Erelzi® | etanercept-szzs | Sandoz | rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis | 08/30/2016 | 92:36 - Disease-modifying Antirheumatic Drugs | 8P/O | |
| Troxyca ER® | oxycodone; naltrexone | Pfizer | severe pain | 08/19/2016 | 28:08.08 - Opiate Agonists; 28:10 - Opiate Antagonists | 4 | |
| Sustol® | granisetron | Heron | prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens | 08/09/2016 | 56:22.20 - 5-HT3 Receptor Antagonists | 5 | |
| Qbrelis® | lisinopril | Silvergate | hypertension; adjunct therapy for heart failure; acute myocardial infarction | 07/29/2016 | 24:32.04 - Angiotensin-Converting Enzyme Inhibitors | 3S | |
| Adlyxin® | lixisenatide | Sanofi-Aventis | type 2 diabetes mellitus | 07/27/2016 | 68:20.06 - Incretin Mimetics | 1 | |
| Viekira XR® | dasabuvir; ombitasvir; paritaprevir; ritonavir | Abbvie | chronic hepatitis C virus (HCV) infection | 07/22/2016 | 8:18.40.16 - HCV Polymerase Inhibitors; 8:18.40.24 - HCV Replication Complex Inhibitors; 8:18.40.20 - HCV Protease Inhibitors | 3 | |
| Photrexa®, Photrexa® Viscous | riboflavin 5'-phosphate | Avedro | for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery | 07/15/2016 | 52:92 - EENT Drugs, Misc | 3P | |
| Belviq XR® | lorcaserin | Arena | adjunct to a reduced-calorie diet and increased physical activity for chronic weight management | 07/15/2016 | 28:20.08.32 - Selective Serotonin Receptor Agonists | 5 | |
| SMOF Lipid® | SMOF (soybean oil, medium-chain triglycerides, olive oil, fish oil) | Fresenius Kabi | parenteral caloric replacement | 07/13/2016 | 40:20 - Caloric Agents | 4 | |
| Xiidra® | lifitegrast | Shire | dry eye disease | 07/11/2016 | 52:08.92 - Anti-inflammatory Agents, Misc | 1P | |
| Syndros® | dronabinol | Insys | treatment of AIDS-related weight loss; chemotherapy-induced nausea/vomiting | 07/01/2016 | 56:22.92 - Antiemetics, Misc | 3S | |
| Kovanaze® | tetracaine; oxymetazoline | St Renatus | regional anesthesia for dental procedures | 06/29/2016 | 52:16 - Local Anesthetics (EENT); 52:32 - Vasoconstrictors (EENT) | 4S | |
| Epclusa® | sofosbuvir; velpatasivir | Gilead | hepatitis C virus infection | 06/28/2016 | 8:18.40.16 - HCV Polymerase Inhibitors; 8:18.40.24 - HCV Replication Complex Inhibitors | 1P | |
| Rayaldee® | calcifediol | Opko | secondary hyperparathyroidism with chronic kidney disease (CKD) | 06/17/2016 | 88:16 - Vitamin D | 5 | |
| Vaxchora® | cholera vaccine live oral | Pax Vax | active immunization against Vibrio cholerae serogroup O1 | 06/10/2016 | 80:12 - Vaccines | B1A | |
| Byvalson® | nebivolol; valsartan | Forest Labs | hypertension | 06/03/2016 | 24:24 - ß-Adrenergic Blocking Agents; 24:32.08 - Angiotensin II Receptor Antagonists | 4 | |
| Netspot® | gallium (Ga 68) dotatate | Advanced Accelerator | radioactive diagnostic agent (somatostatin receptor positive neuroendocrine tumors (NETs)) for PET imaging | 06/01/2016 | 36:68 - Roentgenography | 1 | |
| Axumin® | fluciclovine (18F) | Blue Earth Diagnostics | radioactive diagnostic agent (prostate cancer) for PET imaging | 05/27/2016 | 36:68 - Roentgenography | 1 | |
| Zinbryta® | daclizumab | Biogen | multiple sclerosis | 05/27/2016 | 92:20 - Immunomodulatory Agents | 5P/O | |
| Ocaliva® | obeticholic acid | Intercept | primary biliary cholangitis (PBC) | 05/27/2016 | 56:92 - GI Drugs, Misc | 1 | |
| Probuphine® Implant | buprenorphine | Titan | opioid dependence | 05/26/2016 | 28:08.12 - Opiate Partial Agonists | 3 | |
| Tecentriq® | atezolizumab | Genentech | locally advanced or metastatic urothelial carcinoma | 05/18/2016 | 10:00 - Antineoplastic Agents | 5P/O | |
| Ameluz® 10% Gel | aminolevulinic acid | Biofrontera | actinic keratoses | 05/10/2016 | 84:92 - Skin and Mucous Membrane Agents, Misc | 3S | |
| Nuplazid® | pimavanserin | Acadia | hallucinations and delusions associated with Parkinson's disease psychosis | 04/29/2016 | 28:16.08.04 - Atypical Antipsychotics | 1P | |
| Otovel® Otic | ciprofloxacin; fluocinolone acetonide | Laboratorios Salvat SA | acute otitis media with tympanostomy tubes (AOMT) | 04/29/2016 | 52:04.04 - EENT Antibacterials; 52:08.08 - EENT Corticosteroids | 5 | |
| Akovaz® | ephedrine sulfate | Flamel Ireland | clinically important hypotension occurring in the setting of anesthesia | 04/29/2016 | 12:12.12 - alpha- and beta-Adrenergic Agonists | 7 | |
| Akovaz® | ephedrine sulfate | Exela Pharma | hypotension during anesthesia | 04/29/2016 | 12:12.12 - alpha- and beta-Adrenergic Agonists | 7S | |
| Xtampza® ER | oxycodone | Collegium | severe pain requiring around-the-clock treatment | 04/26/2016 | 28:08.08 - Opiate Agonists | 5 | |
| Acticlate® Capsules | doxycycline hyclate | Aqua | rickettsial infections, STDs, RTIs, anthrax; adjunctive therapy for intestinal amebiasis and severe acne; prophylaxis of malaria | 04/26/2016 | 8:12.24 - Tetracyclines | 5 | |
| Bevespi® Aerosphere | glycopyrrolate; formoterol | Pearl | long-term maintenance treatment of COPD | 04/25/2016 | 12:08.08 - Antimuscarinics/ Antispasmodics; 12:12.08.12 - Selective beta-2-Adrenergic Agonists | 4 | |
| Cabometyx® | cabozantinib (s)-malate | Exelixis | advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy | 04/25/2016 | 10:00 - Antineoplastic Agents | 4e | |
| Venclexta® | venetoclax | Abbvie | chronic lymphocytic leukemia (CLL) | 04/11/2016 | 10:00 - Antineoplastic Agents | P,O | |
| Inflectra® | infliximab-dyyb | Celltrion | Crohn's Disease | 04/05/2016 | 92:36 - Disease-modifying Antirheumatic Drugs | 4P/O | |
| Descovy® | emtricitabine; tenofovir alafenamide (TAF) | Gilead | HIV-1 infection | 04/04/2016 | 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI) | R | |
| Defitelio® | defibrotide | Gentium/Jazz | hepatic veno-occlusive disease (VOD) | 03/30/2016 | 20:12.92 - Antithrombotic Agents, Misc (new) | 1P | |
| Cinqair® | reslizumab | Teva | severe asthma with an eosinophilic phenotype | 03/23/2016 | 48:10.20 - Interleukin Antagonists (updated 2016/04/20); originally posted as 48:92 - Respiratory Agents, Misc | 3P/O | |
| Taltz® | ixekizumab | Eli Lilly | moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy | 03/22/2016 | 84:92 - Skin and Mucous Membrane Agents, Misc | ||
| Anthim® | obiltoxaximab | Elusys | treatment of inhalational anthrax; prophylaxis when alternative therapies not available (for national stockpile) | 03/18/2016 | 80:04 - Antitoxins and Immune Globulins | 3i | |
| Kovaltry® | antihemophilic factor, recombinant | Bayer | hemophilia A (congenital factor VIII deficiency) | 03/17/2016 | 20:28.16 - Hemostatics | 3e | |
| Evomela® | melphalan | Spectrum | high-dose conditioning treatment prior to stem cell transplantation in multiple myeloma; palliative treatment of multiple myeloma when oral therapy is not appropriate | 03/10/2016 | 10:00 - Antineoplastic Agents | 5S | |
| Idelvion® | coagulation factor IX (recombinant), albumin fusion protein (rIX-FP) (albutrepenonacog alfa) | CSL Behring | hemophilia B (congenital Factor IX deficiency) | 03/04/2016 | 20:28.16 - Hemostatics | 3e | |
| Odefsey® | emtricitabine; rilpivirine; tenofovir alafenamide (TAF) | Gilead | HIV-1 infection | 03/01/2016 | 8:18.08.20 - HIV NRTI; 8:18.08.16 - HIV NNRTI; 8:18.08.20 - HIV NRTI | 4 | |
| Xeljanz® XR | tofacitinib | Pfizer | rheumatoid arthritis | 02/23/2016 | 92:36 - Disease-modifying Antirheumatic Agents | 3S | |
| Briviact® | brivaracetam | UCB | adjunctive therapy in the treatment of partial-onset seizures | 02/18/2016 | 28:12.92 - Anticonvulsants, Misc | 1S | |
| Sernivo® | betamethasone dipropionate topical spray | Promius | mild to moderate plaque psoriasis | 02/05/2016 | 84:06 - Anti-inflammatory Agents | 3S | |
| Cetylev® | acetylcysteine | Arbor | acetaminophen overdose/toxicity | 01/29/2016 | 92:12 - Antidotes | 3 | |
| Adzenys XR-ODT® (CII) | amphetamine | Neos | attention deficit hyperactivity disorder (ADHD) | 01/28/2016 | 28:20.04 - Amphetamines | 3 | |
| Zembrace Symtouch® | sumatriptan | Dr Reddys | acute treatment of migraine with or without aura | 01/28/2016 | 28:32.28 - Selective Serotonin Agonists | 5 | |
| Zepatier® | elbasvir; grazoprevir | MSD | hepatitis C virus infection | 01/28/2016 | 8:18.40.24 - HCV Replication Complex Inhibitors; 8:18.40.20 - HCV Protease Inhibitors | 4 | |
| Onzetra Xsail® | sumatriptan | Avanir | acute treatment of migraine with or without aura | 01/27/2016 | 28:32.28 - Selective Serotonin Agonists | 3 | |
| Dexilant® Solutab | dexlansoprazole | Takeda | maintain healting of erosive esophagitis (EE); heartburn associated with non-erosive gastroesophageal reflux disease (GERD) | 01/26/2016 | 56:28.36 - Proton-pump Inhibitors | 3 | |
| E-Z-HD®Readi-Cat 2® | barium sulfate | Bracco | double-contrast radiographic examinations of the esophagus, stomach and duodenum to visualize the GI tract | 01/11/2016 | 36:68 - Roentgenography | 1P | |
| Zurampic® | lesinurad | Ardea | hyperuricemia associated with gout in combination with an XOI | 12/22/2015 | 92:16 - Antigout Agents | 1S | |
| Uptravi® | selexipag | Actelion | pulmonary arterial hypertension (PAH) | 12/21/2015 | 48:48 - Vasodilating Agents | 1S,O | |
| Bridion® | sugammadex | Organon | reversal of neuromuscular blockade induced by rocuronium/vecuronium | 12/14/2015 | 92:12 - Antidotes | 1 | |
| Vistogard® | uridine triacetate | Wellstat | overdosage/toxicity of fluorouracil or capecitabine | 12/11/2015 | 92:12 - Antidotes | 1P/O | |
| Alecensa® | alectinib | Hoffman-LaRoche | anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) | 12/11/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Kanuma® | sebelipase alfa | Alexion | lysosomal acid lipase (LAL) deficiency (Wolman disease; cholesteryl ester storage disease [CESD]) | 12/08/2015 | 44:00 - Enzymes | 1O | |
| Empliciti® | elotuzumab | Bristol-Myers Squibb | multiple myeloma | 11/30/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Portrazza® | necitumumab | Eli Lilly | advanced non-small cell lung cancer (NSCLC) | 11/24/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Ninlaro® | ixazomib | Takeda | multiple myeloma | 11/20/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Darzalex® | daratumumab | Janssen | multiple myeloma | 11/16/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Tagrisso® | osimertinib | AstraZeneca | advanced non-small cell lung cancer (NSCLC) | 11/13/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Adynovate® | antihemophilic factor (recombinant), PEGylated | Baxalta | hemophilia A | 11/13/2015 | 20:28.16 - Hemostatics | 1 | |
| Cotellic® | cobimetinib | Genentech | unresectable or metastatic melanoma | 11/10/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Genvoya® | elvitegravir; cobicistat; emtricitabine; tenofovir | Gilead | HIV-1 | 11/05/2015 | 8:18.08.12 - HIV Integrase Inhibitors; 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors | 1 | |
| Nucala® | mepolizumab | GSK | severe asthma with an eosinophilic phenotype | 11/04/2015 | 48:10 - Anti-Inflammatory Agents | 1 | |
| Seebri® Neohaler | glycopyrrolate | Novartis | chronic obstructive pulmonary disease (COPD) | 10/29/2015 | 12:08.08 - Antimuscarinics/Antispasmodics | 3S | |
| Utibron® Neohaler | indacaterol; glycopyrrolate | Novartis | chronic obstructive pulmonary disease (COPD) | 10/29/2015 | 12:12.08.12 - Selective beta-2-Adrenergic Agonists; 12:08.08 - Antimuscarinics/Antispasmodics | 4S | |
| Imlygic® | talimogene laherparepvec | Amgen | melanoma | 10/27/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Yondelis® | trabectedin | Janssen | liposarcoma, leiomyosarcoma | 10/23/2015 | 10:00 - Antineoplastic Agents | 1P | |
| Strensiq® | asfotase alfa | Alexion | perinatal/infantile- and juvenile-onset hypophosphatasia (HPP) | 10/23/2015 | 44:00 - Enzymes | 1P | |
| Belbuca® | buprenorphine | Endo | severe pain requiring around-the-clock long-term treatment | 10/23/2015 | 28:08.12 - Opiate Partial Agonists | 3S | |
| Veltassa® | patiromer sorbitex calcium | Relypsa | hyperkalemia | 10/21/2015 | 40:18.18 - Potassium-removing Agents | 1 | |
| Coagadex® | Factor X (Human) | Bio Products | hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding | 10/20/2015 | 20:28.16 - Hemostatics | 1 | |
| Praxbind® | idarucizumab | Boehringer Ingelheim | reversal of the anticoagulant effects of dabigatran | 10/16/2015 | 20:28.92 - Antihemorrhagic Agents, Misc (new) | 1 | |
| Aristada® | aripiprazole lauroxil | Alkermes | schizophrenia | 10/05/2015 | 28:16.08.04 - Atypical Antipsychotics | 1 | |
| Tresiba® | insulin degludec | Novo Nordisk | diabetes mellitus | 09/25/2015 | 68:20.08 - Insulins | 1S | |
| Ryzodeg® 70/30 | insulin degludec; insulin aspart | Novo Nordisk | diabetes mellitus | 09/25/2015 | 68:20.08 - Insulins | 4 | |
| Lonsurf® | trifluridine; tipiracil | Taiho | previously treated metastatic colorectal cancer | 09/22/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Tolak® | fluorouracil | Hill Dermac | actinic keratosis lesions of the face, ears, and scalp | 09/18/2015 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 5S | |
| Vraylar® | cariprazine | Forest | schizophrenia and bipolar disorder | 09/17/2015 | 28:16.08.04 - Atypical Antipsychotics | 1 | |
| Xuriden® | uridine triacetate | Wellstat | hereditary orotic aciduria | 09/08/2015 | 92:92 - Other Miscellaneous Therapeutic Agents | 1 | |
| Varubi® | rolapitant | Tesaro | nausea and vomiting associated with emetogenic chemotherapy | 09/01/2015 | 56:22.92 - Antiemetics, Miscellaneous | 1 | |
| Repatha® | evolocumab | Amgen | heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease | 08/27/2015 | 24:06.24 - Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors (new) | 1S | |
| Synjardy® | empagliflozin; metformin | Boehringer Ingelheim | type 2 diabetes mellitus | 08/26/2015 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.04 - Biguanides | 4 | |
| Addyi® | flibanserin | Sprout | female hypoactive sexual desire disorder (HSDD) | 08/18/2015 | 28:92 - Central Nervous System Agents, Miscellaneous | 1S | |
| Bekyree® | desogestrel (0.15 mg); ethinyl estradiol (0.02 mg) | Lupin | contraception | 08/12/2015 | 68:12 - Contraceptives | NU | |
| Isibloom® | desogestrel (0.15 mg); ethinyl estradiol (0.03 mg) | Sandoz | contraception | 08/12/2015 | 68:12 - Contraceptives | NU | |
| Keveyis® | dichlorphenamide | Taro | primary hyperkalemic/ hypokalemic periodic paralysis | 08/07/2015 | 92:26 - Carbonic Anhydrase Inhibitors (updated 2016/05/13); (previously: 92:92 - Other Miscellaneous Therapeutic Agents) | 8P/O | |
| Spritam® | levetiracetam | Aprecia | epilepsy | 07/31/2015 | 28:12.92 - Anticonvulsants, Miscellaneous | 3P | |
| Finacea® | azelaic acid | Abbvie | topical treatment of inflammatory papules and pustules of mild to moderate rosacea | 07/29/2015 | 84:92 - Miscellaneous Skin and Mucous Membrane Agents | 3S | |
| Praluent® | alirocumab | Sanofi Aventis | heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease | 07/24/2015 | 24:06.24 - Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors (new) | 1 | |
| Odomzo® | sonidegib | Novartis | locally advanced basal cell carcinoma (BCC) | 07/24/2015 | 10:00 - Antineoplastic Agents | 1S | |
| Daklinza® | daclatasvir | BMS | chronic HCV genotype 3 infection | 07/24/2015 | 8:18.40.24 - HCV Replication Complex Inhibitors | 1 | |
| Technivie® | ombitasavir; paritaprevir; ritonavir | Bayer | chronic HCV genotype 4 infection | 07/24/2015 | 8:18.40.24 - HCV Replication Complex Inhibitors; 8:18.40.20 - HCV Protease Inhibitors | 5P | |
| Epiduo Forte® | adapalene; benzoyl peroxide | Galderma | acne vulgaris | 07/15/2015 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 5S | |
| Rexulti® | brexpiprazole | Otsuka | schizophrenia; major depressive disorder (MDD) | 07/10/2015 | 28:16.08.04 - Atypical Antipsychotics | 1 | |
| Envarsus XR® | tacrolimus | Veloxis | prophylaxis of kidney transplant rejection | 07/10/2015 | 92:44 - Immunosuppressive Agents | 3S | |
| Entresto® | sacubitril; valsartan | Novartis | heart failure | 07/07/2015 | 24:32.92 - Renin-Angiotensin-Aldosterone System Inhibitors, Misc (new); 24:32.08 - Angiotensin II Receptor Antagonists | 1 | |
| Orkambi® | lumacaftor; ivacaftor | Vertex | cystic fibrosis | 07/02/2015 | 48:14.04 - Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Correctors; 48:14.12 - Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiators | 1 | |
| Kengreal® | cangrelor tetrasodium | Medicines Co. | percutaneous coronary intervention (PCI) | 06/22/2015 | 20:12.18 - Platelet-aggregation Inhibitors | 1S | |
| Viberzi® | eluxadoline | Furiex Pharma | irritable bowel syndrome with diarrhea (IBS-D) | 05/27/2015 | 56:92 - GI Drugs, Miscellaneous | 1 | |
| Stiolto Respimat® | tiotropium; olodaterol | Boehringer Ingelheim | chronic obstructive pulmonary disease (COPD) | 05/21/2015 | 12:08.08 - Antimuscarinics/ Antispasmodics; 12:12.08.12 - Selective ß2-Adrenergic Agonists | 1 | |
| Invega Trinza® | paliperidone | Janssen | schizophrenia | 05/18/2015 | 28:16.08.04 - Atypical Antipsychotics | 5 | |
| Ixinity® | coagulation factor IX (recombinant) | Cangene | control and prevention of bleeding episodes in hemophilia B and for perioperative management | 05/14/2015 | 20:28.16 - Hemostatics | NUA | |
| Hycofenix® | hydrocodone; pseudoephedrine; guaifenesin | Mikart | symptomatic relief of cough, nasal congestion, and to loosen mucus associated with the common cold | 05/14/2015 | 48:08 - Antitussives; 12:12.12 - a- and ß-adrenergic agonists; 48:16 - Expectorants | 4 | |
| Flowtuss® | hydrocodone; guaifenesin | Mikart | symptomatic relief of cough and to loosen mucus associated with the common cold | 05/14/2015 | 48:08 - Antitussives; 48:16 - Expectorants | 4 | |
| Raplixa® | fibrin sealant (human) | The Medicines Company | hemostasis for mild to moderate bleeding during surgery | 04/30/2015 | 84:92 - Skin and Mucous Membrane Agents, Misc | 1 | |
| Kybella® | deoxycholic acid | Kythera | reduction of localized subcutaneous fat deposits in the submental region | 04/29/2015 | 92:92 - Other Miscellaneous Therapeutic Agents | 1 | |
| Aptensio XR® | methylphenidate | Rhodes | ADHD | 04/17/2015 | 28:20.32 - Respiratory and CNS Stimulants | 3S | |
| Glatopa® | glatiramer acetate | Sandoz | multiple sclerosis (MS) | 04/16/2015 | 92:20 - Immunomodulatory Agents | 4 | |
| Corlanor® | ivabradine | Amgen | angina pectoris | 04/15/2015 | 24:04.92 - Cardiac Drugs, Miscellaneous | 1P | |
| Jadenu® | deferasirox | Novartis | iron toxicity | 03/30/2015 | 64:00 - Heavy Metal Antagonists | 5P | |
| Evarrest® | fibrin sealant patch (fibrinogen; thrombin) | Omrix | hemostasis during surgery | 03/26/2015 | 84:92 - Skin and Mucous Membrane Agents, Misc | MUB | |
| Cholbam® | cholic acid | Asklepion | bile acid synthesis disorders due to single enzyme defects | 03/17/2015 | 56:92 - GI Drugs, Miscellaneous | 1P | |
| Unituxin® | dinutuximab | United | pediatric patients with high-risk neuroblastoma | 03/10/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Zarxio® | filgrastim-sndz | Sandoz | neutropenia | 03/06/2015 | 20:16 - Hematopoietic Agents | 1 | |
| Cresemba® | isavuconazonium sulfate | Astellas | invasive aspergillosis or mucomycosis | 03/06/2015 | 8:14.08 - Azoles | 1 | |
| Avycaz® | ceftazidime; avibactam | Cerexa | complicated intra-abdominal infections (cIAI); complicated urinary tract infections (cUTI) | 02/25/2015 | 8:12.06.12 - Third Generation Cephalosporins; beta-lactamase inhibitor | 1P | |
| Toujeo® | insulin glargine | Sanofi Aventis | diabetes mellitus | 02/25/2015 | 68:20.08 - Insulins | 5S | |
| Farydak® | panobinostat | Novartis | multiple myeloma | 02/23/2015 | 10:00 - Antineoplastic Agents | 1P | |
| Lenvima® | lenvatinib | Eisai | differentiated thyroid cancer (DTC) | 02/13/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Dutrebis® | lamivudine; raltegravir | Merck Sharp Dohme | HIV infection | 02/06/2015 | 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; 8:18.08.12 - HIV Integrase Inhibitors | 4 | |
| Ibrance® | palbociclib | Pfizer | ER+, HER2- advanced breast cancer in post-menopausal women | 02/03/2015 | 10:00 - Antineoplastic Agents | 1 | |
| Glyxambi® | empagliflozin; linagliptin | Boehringer Ingelheim | type 2 diabetes mellitus | 01/30/2015 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.05 - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors | 4S | |
| Prezcobix® | darunavir; cobicistat | Janssen | HIV infection | 01/29/2015 | 8:18.08.08 - HIV Protease Inhibitors; 92:92 - Other Miscellaneous Therapeutic Agents | 4S | |
| Evotaz® | atazanavir; cobicistat | BMS | HIV infection | 01/29/2015 | 8:18.08.08 - HIV Protease Inhibitors; 92:92 - Other Miscellaneous Therapeutic Agents | 4S | |
| Natpara® | parathyroid hormone | NPS | hypocalcemia in patients with hypoparathyroidism | 01/23/2015 | 68:24 - Parathyroid | PUM | |
| Triferic® | ferric pyrophosphate citrate | Rockwell | iron deficiency in patients with hemodialysis-dependent chronic kidney disease (HDD-CKD) | 01/23/2015 | 20:04.04 - Iron Preparations | 5S | |
| Cosentyx® | secukinumab | Novartis | plaque psoriasis | 01/21/2015 | 84:92 - Skin and Mucous Membrane Agents, Miscellaneous | 1P/O | |
| Prestalia® | perindopril; amlodipine | Symplmed | hypertension | 01/21/2015 | 24:08.44.04 - Angiotensin-Converting Enzyme (ACE) Inhibitors; 24:28.08 - Dihydropyridines | 4S | |
| phoxillum | phoxillum | Gambro Lundia | replacement solution in Continuous Renal Replacement Therapy (CRRT) | 01/13/2015 | 40:12 - Replacement Preparations | 1 | |
| prismasol | prismasol | Gambro Lundia | replacement solution in Continuous Renal Replacement Therapy (CRRT) | 01/13/2015 | 40:12 - Replacement Preparations | 1C | |
| Savaysa® | edoxaban tosylate | Daiichi Sankyo | atrial fibrillation (AF); deep vein thrombosis (DVT); pulmonary embolism (PE) | 01/08/2015 | 20:12.04.14 - Direct Factor Xa Inhibitors | 1S | |
| Rytary® | carbidopa/ levodopa | Impax | Parkinson's disease | 01/07/2015 | 28:36.16 - Dopamine Precursors | 5S | |
| Dyloject® | diclofenac sodium | Javelin | intravenous NSAID; acute moderate-to-severe pain in adults | 12/23/2014 | 28:08.04.92 - Other Non-steroidal Anti-inflammatory Drugs | 3 | |
| Saxenda® | liraglutide | Novo Nordisk | chronic weight management | 12/23/2014 | 68:20.06 - Incretin Mimetics | 10S | |
| Namzaric® | memantine/ donepezil | Forest | Alzheimer's disease | 12/23/2014 | 28:92 - Central Nervous System Agents, Misc; 12:04 - Parasympathomimetic (Cholinergic) Agents | 4 | |
| Opdivo® | nivolumab | BMS | unresectable or metastatic melanoma and disease progression following ipilimumab treatment; metastatic squamous non-small cell lung cancer | 12/22/2014 | 10:00 - Antineoplastic Agents | - | |
| Lynparza® | olaparib | AstraZeneca | advanced ovarian cancer | 12/19/2014 | 10:00 - Antineoplastic Agents | 1P | |
| Soolantra® | ivermectin | Galderma | rosacea | 12/19/2014 | 84:04.12 - Scabicides and Pediculisides | 1 | |
| Rapivab® | peramivir | BioCryst | influenza | 12/19/2014 | 8:18.28 - Neuraminidase Inhibitors | 1S | |
| Viekira Pak® | ombitasvir/ paritaprevir/ ritonavir; dasabuvir | Abbvie | genotype 1 chronic hepatitis C virus (HCV) infection | 12/19/2014 | 8:18.40.24 - HCV Replication Complex Inhibitors; 8:18.40.20 - HCV Protease Inhibitors; —; 8:18.40.16 - HCV Polymerase Inhibitors | 4P | |
| Zerbaxa® | ceftolozane/ tazobactam | Cubist | complicated intra-abdominal infections and urinary tract infections | 12/19/2014 | 8:12.06.12 - Third Generation Cephalosporins; — (previously posted as 4th Gen) | 4 | |
| Xtoro® | finafloxacin | Alcon | acute otitis externa | 12/17/2014 | 52:04.04 - Antibacterials (EENT) | 1P | |
| Signifor LAR® | pasireotide | Novartis | acromegaly | 12/15/2014 | 68:29.04 - Somatostatin Agonists | 5S | |
| Blincyto® | blinatumomab | Amgen | Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) | 12/03/2014 | 10:00 - Antineoplastic Agents | 1 | |
| TrezixTM | acetaminophen; caffeine; dihydrocodeine | Wraser | moderate to moderately severe pain | 11/26/2014 | 28:08.92 - Analgesics and Antipyretics, Misc; 28:20.32 - Respiratory and CNS Stimulants; 28:08.08 - Opiate Agonists | DUE | |
| Hysingla ER® | hydrocodone bitartrate | Purdue | severe, around-the-clock, pain management | 11/20/2014 | 28:08.08 - Opiate Agonists | 3 | |
| Yaela® | drospirenone; ethinyl estradiol | Novast | birth control | 11/19/2014 | 68:12 - Contraceptives | RUD | |
| Obredon® | hydrocodone/guaifenesin oral solution | Sovereign | symptomatic relief of cough and to loosen mucous associated with the common cold | 11/14/2014 | 48:08 - Antitussives; 48:16 - Expectorants | 4 | |
| Lemtrada® | alemtuzumab | Genzyme | multiple sclerosis | 11/04/2014 | 92:20 - Immunomodulatory Agents | 1P/O | |
| Trumenba® | Meningococcal Group B Vaccine | Wyeth | immunization against serogroup B meningococcal disease | 10/29/2014 | 80:12 - Vaccines | ||
| Xigduo XR® | dapagliflozin/metformin | AstraZeneca | type 2 diabetes mellitus | 10/29/2014 | 68:20.18 - SGLT2 Inhibitors; 68:20.04 - Biguanides | 4S | |
| Bexsero® | meningococcal group B vaccine | GlaxoSmithKline | active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B | 10/29/2014 | 80:12 - Vaccines | ||
| Obizur® | antihemophilic factor (recombinant), porcine sequence | Baxter | acquired hemophilia A (acquired Factor VIII [FVII] deficiency) | 10/24/2014 | 20:28.16 - Hemostatics | 1e | |
| Sotylize® | sotalol oral solution | Arbor | ventricular arrhythmias; atrial fibrillation/flutter | 10/22/2014 | 24:24 - ß-Adrenergic Blocking Agents | 3S | |
| Ofev® | nintedanib | Boehringer Ingelheim | idiopathic pulmonary fibrosis (IPF) | 10/15/2014 | 48:92 - Respiratory Agents, Miscellaneous | 1 | |
| Esbriet® | pirfenidone | InterMune (Roche) | idiopathic pulmonary fibrosis (IPF) | 10/15/2014 | 48:92 - Respiratory Agents, Miscellaneous | 1 | |
| Lumason® | sulfur hexafluoride lipid-type A microspheres | Bracco | echocardiograms | 10/10/2014 | 36:68 - Roentgenography | 1S | |
| Akynzeo® | netupitant; palonosetron | Helsinn | prevention of acute and delayed nausea and vomiting due to highly emetogenic chemotherapy | 10/10/2014 | 56:22.92 - Antiemetics, Misc; 56:22.20 - 5-HT3-receptor Antagonists | 1S | |
| Harvoni® | ledipasvir; sofosbuvir | Gilead | Hepatitis C virus infection | 10/10/2014 | 8:18.40.24 - HCV Replication Complex Inhibitors; 8:18.40.16 - HCV Polymerase Inhibitors | 1P | |
| Uceris® | budesonide rectal foam | Salix | ulcerative colitis | 10/07/2014 | 68:04 - Adrenals | 3S | |
| Mitigare® | colchicine | Hikma | prophylaxis of gout flares | 09/26/2014 | 92:16 - Antigout Agents | 3 | |
| Vitekta® | elvitegravir | Gilead | human immunodeficiency virus type 1 (HIV-1) infection | 09/24/2014 | 8:18.08.12 - HIV Integrase Inhibitors | 5 | |
| Tybost® | cobicistat | Gilead | pharmacologic enhancer to decrease metabolism, and increase plasma concentrations, of antiretroviral agents | 09/24/2014 | 92:92 - Other Miscellaneous Therapeutic Agents | 5 | |
| Iluvien® | fluocinolone acetonide intravitreal implant | Alimera | diabetic macular edema | 09/24/2014 | 52:08.08 - Corticosteroids | 3 | |
| Otezla® Injectable | apremilast | Celgene | psoriatic arthritis | 09/23/2014 | 92:36 - Disease-modifying Antirheumatic Drugs (DMARDs) | 1 | |
| Trulicity® | dulaglutide | Eli Lilly | type 2 diabetes mellitus | 09/18/2014 | 68:20.06 - Incretin Mimetics | 1 | |
| Movantik® | naloxegol | AstraZeneca | opioid-induced constipation (OIC) | 09/16/2014 | 56:92 - GI Drugs, Miscellaneous | 1P | |
| Setlakin® | ethinyl estradiol; levonorgestrel | Novast | birth control | 09/15/2014 | 68:12 - Contraceptives | RUT | |
| Emsam® | selegiline | Somerset | depression | 09/10/2014 | 28:36.32 - Monoamine Oxidase B Inhibitors | 6S | |
| Contrave® | naltrexone; bupropion | Orexigen | chronic weight management | 09/10/2014 | 28:20.08.92 - Anorexigenic Agents, Miscellaneous | 4 | |
| Zerenex® | ferric citrate | Keryx | hyperphosphatemia | 09/05/2014 | 40:18.19 - Phosphate-removing Agents | 5 | |
| Keytruda® | pembrolizumab | MSD | metastatic melanoma | 09/04/2014 | 10:00 - Antineoplastic Agents | 1 | |
| Triumeq® | abacavir; dolutegravir; lamivudine | Viiv | HIV infection | 08/22/2014 | 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NNRTI); 8:18.08.12 - HIV Integrase Inhibitors; 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NNRTI) | 4S | |
| Arnuity Ellipta® | fluticasone | GlaxoSmithKline | asthma | 08/20/2014 | 68:04 - Adrenals | 5S | |
| Cerdelga® | eliglustat | Genzyme | type 1 Gaucher disease | 08/19/2014 | 92:92 - Other Miscellaneous Therapeutic Agents | 8P/O | |
| Plegridy® | peginterferon beta-1A | Biogen Idec | multiple sclerosis | 08/15/2014 | 92:20 - Immunomodulatory Agents | ||
| Belsomra® | suvorexant | Merck | insomnia | 08/13/2014 | 28:24.92 - Anxiolytics, Sedatives, and Hypnotics; Miscellaneous | 1S | |
| Invokamet® | canagliflozin; metformin | Janssen | type 2 diabetes mellitus | 08/08/2014 | 68:20.18 - SGLT2 Inhibitors; 68:20.04 - Biguanides | 1S | |
| Orbactiv® | oritavancin | Medicines Co | acute bacterial skin and skin structure infections (ABSSSI) | 08/06/2014 | 8:12.28.16 - Glycopeptides | 1S | |
| Jardiance® | empagliflozin | Boehringer Ingelheim | type 2 diabetes mellitus | 08/01/2014 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor | 1S | |
| Striverdi® | olodaterol | Boehringer Ingelheim | chronic obstructive pulmonary disease(COPD), including chronic bronchitis and/or emphysema | 07/31/2014 | 12:12.08.12 - Selective ß2-Adrenergic Agonists | 1 | |
| Zydelig® | idelalisib | Gilead | chronic lymphocytic leukemia (CLL); relapsed follicular B-cell non-Hodgkin lymphoma (FL); relapsed small lymphocytic lymphoma (SLL) | 07/23/2014 | 10:00 - Antineoplastic Agents | 1 | |
| Kerydin® | tavaborole | Anacor | onychomycosis (nail fungus) | 07/07/2014 | 84:04.08.24 - Oxaboroles (New) | 1 | |
| Beleodaq® | belinostat | Spectrum | peripheral T-cell lymphoma (PTCL) | 07/03/2014 | 10:00 - Antineoplastic Agents | 1 | |
| Afrezza® | insulin recombinant human inhalation powder | Sanofi Aventis | diabetes mellitus | 06/27/2014 | 68:20.08 - Insulins | 5S | |
| Sivextro® | tedizolid | Cubist | acute bacterial skin and skin structure infections | 06/20/2014 | 8:12.28.24 - Oxazolidinones | 1 | |
| Jublia® | efinaconazole | Dow | onchomycosis of the toenails | 06/06/2014 | 84:04.08.08 - Azoles | 1 | |
| Eloctate® | Antihemophilic Factor (Recombinant), Fc Fusion Protein | Biogen Idec | hemophilia A; treatment and prophylaxis of bleeding episodes | 06/06/2014 | 20:28.16 - Hemostatics | 1 | |
| Bunavail® | buprenorphine; naloxone | Biodelivery Sciences | maintenance treatment of opioid dependence | 06/06/2014 | 28:08.12 - Opiate Partial Agonists | 3S | |
| Omidria® | phenylephrine; ketorolac | Omeros | prevent intraoperative miosis and reduce postoperative pain during cataract surgery or intraocular lens replacement | 05/30/2014 | 52:24 - Mydriatics; 52:08.20 - Nonsteroidal Anti-inflammatory Agents | 4S | |
| Natesto® | testosterone | Trimel Biopharma | testosterone replacement therapy | 05/28/2014 | 68:08 - Androgens | 5S | |
| Dalvance® | dalbavancin | Durata | acute bacterial skin infections caused by Gram+ organisms | 05/23/2014 | 8:12.28.16 - Glycopeptides | 1 | |
| Entyvio® | vedolizumab | Takeda | ulcerative colitis; Crohn's Disease | 05/19/2014 | 56:92 - GI Drugs, Miscellaneous | 1 | |
| Izba® | travoprost | Alcon | open-angle glaucoma or ocular hypertension | 05/15/2014 | 52:40.28 - Prostaglandin Analogs | 5 | |
| Zontivity® | vorapaxar | Merck | reduce the risk of heart attack, stroke, cardiovascular death | 05/08/2014 | 20:12.18 - Platelet-aggregation Inhibitors | 1 | |
| Epanova® | omega-3 carboxylic acids | AstraZeneca | hypertriglyceridemia | 05/05/2014 | 24:06.92 - Antilipemic Agents, Misc | 5 | |
| Incruse Ellipta® | umeclidinium | GlaxoSmithKline | chronic obstructive pulminary disorder (COPD) | 04/30/2014 | 12:08.08 - Antimuscarinics/ Antispasmodics | 5 | |
| Zykadia® | ceritinib | Novartis | late-stage (metastatic) non-small cell lung cancer (NSCLC) | 04/29/2014 | 10:00 - Antineoplastic Agents | 5 | |
| Chemet® | succimer | Recordati | lead poisoning | 04/23/2014 | 64:00 - Heavy Metal Antagonists | 1P,O | |
| Omtryg® | omega-3 acid ethyl esters | Trygg Pharma | hypertriglyceridemia | 04/23/2014 | 24:06.92 - Antilipemic Agents, Misc | 5 | |
| Sylvant® | siltuximab | Janssen | multicentric Castleman's disease (MCD) | 04/22/2014 | 10:00 - Antineoplastic Agents | 4( | |
| Cyramza® | ramucirumab | Eli Lilly | gastric cancer | 04/21/2014 | 10:00 - Antineoplastic Agents | SUU | |
| Ragwitek® | short ragweed pollen allergen extract | MSD | allergic rhinitis | 04/17/2014 | 92:92 - Other Miscellaneous Therapeutic Agents (moved to 80:02 - Allergenic Extracts) | LUR | |
| Tanzeum® | albiglutide | GlaxoSmithKline | type 2 diabetes mellitus | 04/15/2014 | 68:20.06 - Incretin Mimetics | PUT | |
| Grastek® | grass pollen allergen extract (Timothy Grass Pollen Allergen Extract) | MSD | allergic rhinitis | 04/11/2014 | 92:92 - Other Miscellaneous Therapeutic Agents (moved to 80:02 - Allergenic Extracts) | LUA | |
| Evzio® | naloxone | Kaleo | emergency treatment of opioid overdose | 04/03/2014 | 28:10 - Opiate Antagonists | 3 | |
| Oralair® | grass pollen allergen extract (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) | Stallergenes | allergic rhinitis | 04/02/2014 | 92:92 - Other Miscellaneous Therapeutic Agents (moved to 80:02 - Allergenic Extracts) | LUA | |
| Alprolix® | Coagulation Factor IX (Recombinant), Fc Fusion Protein | Biogen Idec | control and prevention of bleeding episode in patients with hemophilia B | 03/28/2014 | 20:28.16 - Hemostatics | NUT | |
| Otezla® Oral | apremilast | Celgene | psoriatic arthritis | 03/21/2014 | 92:36 - Disease-modifying Antirheumatic Drugs (DMARDs) | 1 | |
| Neuraceq® | florbetaben | Primal Imaging | PET imaging of the brain | 03/19/2014 | 36:68 - Roentgenography | 1 | |
| Impavido® | miltefosine | Paladin Therapeutics | visceral, cutaneous, and mucosal leishmaniasis | 03/19/2014 | 8:30.92 - Antiprotozoals, Misc | 1 | |
| Myalept® | metreleptin | Amylan | leptin deficiency in congenital or acquired generalized lipodystrophy | 02/24/2014 | 68:40 - Leptins (New) | PUP | |
| Tivorbex® | indomethacin | Iroko | mild to moderate acute pain | 02/24/2014 | 28:08.04.92 - Other Nonsteroidal Anti-inflammatory Agents | 3 | |
| Northera® | droxidopa | Chelsea Therapeutics | neurogenic orthostatic hypotension | 02/18/2014 | 12:12.12 - a- and ß-Adrenergic Agonists | 1 | |
| Vimizim® | elosulfase alfa | Biomarin | mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) | 02/14/2014 | 44:00 - Enzymes | 2r | |
| Imbruvica® | ibrutinib | Pharmacyclics | mantle cell lymphoma | 02/12/2014 | 10:00 - Antineoplastic Agents | 1P | |
| Hetlioz® | tasimelteon | Vanda | non-24-hour sleep-wake disorder | 01/31/2014 | 28:24.92 - Anxiolytics, Sedatives, and Hypnotics, Misc. | 1 | |
| Farxiga® | dapagliflozin | BMS | type 2 diabetes mellitus | 01/08/2014 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor | 1S | |
| Orenitram® | treprostinil diolamine | United Therapeutics | pulmonary arterial hypertension (PAH) | 12/20/2013 | 48:48 - Vasodilating Agents | 3S;O | |
| Kuvan® | sapropterin | Biomarin | hyperphenylalaninemia (HPA) | 12/19/2013 | 92:92 - Other Miscelaneous Therapeutic Agents | 3S;O | |
| Anoro Ellipta® | umeclidinium; vilanterol | Glaxo | chronic obstructive pulmonary disease (COPD) | 12/18/2013 | 12:08.08 - Antimuscarinics/ Antispasmodics; 12:12.08.12 - Selective ß2-Adrenergic Agonists | 1 | |
| Sovaldi® | sofosbuvir | Gilead | chronic hepatitis C (CHC) infection | 12/06/2013 | 8:18.32 - Nucleosides and Nucleotides | 1 | |
| Velphoro® | sucroferric oxyhydroxide | Vifor Fresenius | hyperphosphatemia in dialysized patients | 11/27/2013 | 40:18.19 - Phosphate-removing Agents | 5 | |
| Varithena® | polidocanol | Provensis | varicose (spider and reticular) veins | 11/25/2013 | 24:16 - Sclerosing Agents | 5 | |
| Olysio® | simeprevir | Janssen | chronic hepatitis C infection | 11/22/2013 | 8:18.40 - HCV Protease Inhibitors | 1 | |
| influenza A (H5N1) virus monovalent vaccine | influenza A (H5N1) virus monovalent vaccine | Sanofi Pasteur | avian influenza; for national stockpile only; no commercial products | 11/22/2013 | 80:12 - Vaccines | 1 | |
| Luzu® | luliconazole | Medicis | interdigital tinea pedis, tinea cruris, tinea corporis | 11/14/2013 | 84:04.08.08 - Azoles | 1S | |
| Imbruvica® | ibrutinib | Pharmacyclics | mantle cell lymphoma (MCL) | 11/13/2013 | 10:00 - Antineoplastic Agents | 1 | |
| Aptiom® | eslicarbazepine | Sunovion | partial seizures | 11/08/2013 | 28:12.92 - Anticonvulsants, Misc | 1S | |
| Gazyva® | obinutuzumab | Genentech | chronic lymphocytic leukemia (CLL) | 11/01/2013 | 10:00 - Antineoplastics | 1( | |
| Zohydro ER® | hydrocodone | Zogenix | severe pain | 10/25/2013 | 28:08.08 - Opiate Agonists | 3 | |
| Vizamyl® | flutemetamol F18 | GE Healthcare | PET imaging of the brain | 10/25/2013 | 36:68 - Roentgenography | 1S | |
| Ecoza® | econazole | Amderma | interdigital tinea pedis | 10/24/2013 | 84:04.08.08 - Azoles | 3 | |
| Opsumit® | macitentan | Actelion | pulmonary arterial hypertension | 10/18/2013 | 24:12.92 - Vasodilating Agents, Misc | 1 | |
| Zorvolex® | diclofenac | Iroko | mild to moderate acute pain | 10/18/2013 | 28:08.04.92 - Other Nonsteroidal Anti-inflammatory Agents | 3 | |
| Otrexup® | methotrexate | Antares | rheumatoid arthritis; psoriasis | 10/11/2013 | 92:36 - Disease-modifying Antirheumatic Drugs | 5S | |
| Adempas® | riociguat | Bayer | pulmonary hypertension (CTEPH / PAH) | 10/08/2013 | 24:12.92 - Vasodilating Agents, Misc | 1 | |
| Duavee® | conjugated estrogens / bazedoxifene | Wyeth | vasomotor symptoms associated with menopause | 10/03/2013 | 68:16.12 - Estrogen Agonists-Antagonists | 4 | |
| Clinolipid® | lipid | Baxter | parenteral nutrition | 10/03/2013 | 40:20 - Caloric Agents | 5 | |
| Brintellix® | vortioxetine | Takeda | major depressive disorder | 09/30/2013 | 28:16.04.24 - Serotonin Modulators | 1S | |
| Mirvaso® | brimonidine | Galderma | facial erythema of rosacea | 08/26/2013 | 84:92 - Skin and Mucous Membrane Agents, Misc | 3 | |
| Valchlor® | mechlorethamine | Ceptaris | fungoides-type cutaneous T-cell lymphoma | 08/23/2013 | 84:92 - Skin and Mucous Membrane Agents, Misc | 5S | |
| Tivicay® | dolutegravir | Viiv | HIV-1 infection | 08/12/2013 | 8:18.08.12 - Integrase Inhibitors | 1 | |
| Injectafer® | ferric carboxymaltose | Luitpold | iron deficiency anemia | 07/25/2013 | 20:04.04 - Iron Preparations | 5 | |
| Fetzima® | levomilnacipran | Forest | major depressive disorder | 07/25/2013 | 28:16.04.16 - Selective Serotonin- and Norepinephrine-reuptake Inhibitors | 5 | |
| Gilotrif® | afatinib | Boehringer Ingelheim | metastatic non-small cell lung cancer | 07/12/2013 | 10:00 - Antineoplastic Agents | 1 | |
| Khedezla® | desvenlafaxine | Osmotica | major depressive disorder | 07/10/2013 | 28:16.04.16 - Selective Serotonin- and Norepinephrine-reuptake Inhibitors | 5 | |
| Zubsolv® | buprenorphine / naloxone | Orexo | maintenance treatment of opioid dependence | 07/03/2013 | 28:08.12 - Opiate Partial Agonists | 5 | |
| Brisdelle® | paroxetine | Noven | moderate to severe vasomotor symptoms associated with menopause | 06/30/2013 | 28:16.04.20 - Selective Serotonin-reuptake Inhibitors | 3 | |
| Tafinlar® | dabrafenib | GSK | advanced or unresectable melanoma | 05/29/2013 | 10:00 - Antineoplastic Agents | 1 | |
| Mekinist® | trametinib | GSK | advanced or unresectable melanoma | 05/29/2013 | 10:00 - Antineoplastic Agents | 1 | |
| Xofigo® | radium (Ra223) | Bayer | advanced prostate cancer with metastasis to bone | 05/15/2013 | 78:00 - Radioactive Agents | 1P | |
| Breo Ellipta® | fluticasone / vilanterol | Glaxo | COPD | 05/10/2013 | 68:04 - Adrenals; 12:12.08.12 - Selective ß2-Adrenergic Agonists | 1 | |
| Procysbi® Capsules | cysteamine bitartrate | Raptor | nephropathic cystinosis | 04/30/2013 | 92:92 - Other Misc Therapeutic Agents | 5S | |
| Kcentra® | prothrombin complex concentrate (human) | CSL Behring | urgent reversal of VKA (e.g., warfarin) in acute major bleeding episodes | 04/29/2013 | 20:28.16 - Hemostatics | 4s | |
| Pirmella™ 7/7/7 & 1/35 | ethinyl estradiol; norethindrone | Lupin | birth control | 04/24/2013 | 68:12 - Contraceptives | 3 | |
| Simbrinza® | brinzolamide; brimonidine | Alcon | open-angle glaucoma; ocular hypertension | 04/19/2013 | 52:40.04 - a-Adrenergic Agonists; 52:40.12 - Carbonic Anhydrase Inhibitors | 4 | |
| Minastrin® 24 FE | ethinyl estradiol; norethindrone; ferrous fumerate | Warner Chilcott | birth control | 04/19/2013 | 68:12 - Contraceptives | 3 | |
| Sitavig® | acyclovir | Bioalliance | recurrent herpes labialis (cold sores) | 04/12/2013 | 84:04.06 - Antivirals | 3S | |
| Daysee™ | ethinyl estradiol; levonorgestrel | Lupin | birth control | 04/10/2013 | 68:12 - Contraceptives | 3 | |
| Diclegis® | doxylamine; pyridoxine | Duchesnay | morning sickness | 04/09/2013 | 56:22.92 - Antiemetics, Misc | 4 | |
| Prolensa® | bromfenac | Bausch+Lomb | postoperative pain and inflammation after cataract surgery | 04/05/2013 | 52:08.20 - Nonsteroidal Anti-inflammatory Agents | 5 | |
| Invokana® | canagliflozin | Janssen | type 2 diabetes | 03/29/2013 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors (New class) | 1 | |
| Karbinal® ER | carbinoxamine | Tris | seasonal and perennial allergic rhinitis; urticaria; angioedema | 03/28/2013 | 4:04 - First Generation Antihistamines | 3S | |
| Jencycla™ | norethindrone | Lupin | birth control | 03/28/2013 | 68:12 - Contraceptives | 3P/O | |
| Quartette® | levonorgestrel; ethinyl estradiol | Teva | birth control | 03/28/2013 | 68:12 - Contraceptives | 5 | |
| Tecfidera® | dimethyl fumerate | Biogen Idec | multiple sclerosis | 03/27/2013 | 92:20 - Biologic Response Modifiers | 1 | |
| botulism antitoxin heptavalent (equine) | BAT | Cangene | botulism | 03/22/2013 | 80:04 - Serums | 1 | |
| Dotarem® | gadoterate meglumine | Guerbet | for use in MRIs of CNS | 03/20/2013 | 36:68 - Roentgenography | 1S | |
| Lymphoseek® | technetium Tc99 tilmanocept | Navidea | lymph node mapping | 03/13/2013 | 36:68 - Roentgenography | 1S | |
| Enskyce™ | desogestrel; ethinyl estradiol | Lupin | birth control | 03/07/2013 | 68:12 - Contraceptives | O | |
| Osphena® | ospemifene | Shionogi | menopausal dyspareunia | 02/26/2013 | 68:16.12 - Estrogen Agonists-Antagonists | 1S | |
| Stivarga® | regorafenib | Bayer | metastatic colorectal cancer | 02/25/2013 | 10:00 - Antineoplastic Agents | 1P | |
| Kadcyla® | ado-trastuzumab emtansine | Genentech | metastatic HER2 breast cancer | 02/22/2013 | 10:00 - Antineoplastic Agents | 1 | |
| Pomalyst® | pomalidomide | Celgene | multiple myeloma | 02/08/2013 | 10:00 - Antineoplastic Agents | 1 | |
| Versacloz® | clozapine | Douglas | schizophrenia | 02/06/2013 | 28:16.08.04 - Atypical Antipsychotics | 3 | |
| Ravicti® | glycerol phenylbutyrate | Hyperion | urea cycle disorders (UCD) | 02/01/2013 | 40:10 - Ammonia Detoxicants | 2S/O | |
| Delzicol® | mesalamine | Warner Chilcott | ulcerative colitis | 02/01/2013 | 56:36 - Anti-inflammatory Agents | 3S | |
| Kynamro® | mipomersen | Genzyme | homozygous familial hyper-cholesterolemia (HoFH) | 01/29/2013 | 24:06.92 - Antilipemic Agents, Miscellaneous | 1 | |
| Nesina® | alogliptin | Takeda | type 2 diabetes mellitus | 01/25/2013 | 68:20.05 - DPP-4 Inhibitors | 1 | |
| Oseni® | alogliptin; pioglitazone | Takeda | type 2 diabetes mellitus | 01/25/2013 | 68:20.05 - DPP-4 Inhibitors; 68:20.28 - Thiazolidinediones | 1 | |
| Kazano® | alogliptin; metformin | Takeda | type 2 diabetes mellitus | 01/25/2013 | 68:20.05 - DPP-4 Inhibitors; 68:20.04 - Biguanides | 1 | |
| Zecuity® | sumatriptan | Nupathe | migraine headache | 01/17/2013 | 28:32.28 - Selective Serotonin Agonists | 3 | |
| Uceris® | budesonide extended-release tablets | Santarus | ulcerative colitis | 01/14/2013 | 68:04 - Adrenals | 5S | |
| Skyla® | levonorgestrel | Bayer | birth control | 01/09/2013 | 68:12 - Contraceptives | 5 | |
| Arzerra® | ofatumumab | Novartis | chronic lymphocytic leukemia (CLL) | 10/26/2009 | 10:00 - Antineoplastic Agents | 1( |